# Atrial fibrillation

*comorbidities, lifestyle, and patient factors*

Shantsila, Eduard; Choi, Eue-Keun; Lane, Deirdre A.; Joung, Boyoung; Lip, Gregory Y. H.

*Published in:*
The Lancet Regional Health - Europe

*DOI (link to publication from Publisher):*
10.1016/j.lanepe.2023.100784



*Publication date:*
2024

*Document Version*
Publisher's PDF, also known as Version of record

# Atrial Fibrillation

## Atrial fibrillation: comorbidities, lifestyle, and patient factors

Eduard Shantsila,[a,b,g,*] Eue-Keun Choi,[c] Deirdre A. Lane,[b,d,f] Boyoung Joung,[e] and Gregory Y. H. Lip[b,d,f]

[a]Department of Primary Care and Mental Health, University of Liverpool, United Kingdom
[b]Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
[c]Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
[d]Department of Cardiovascular and Metabolic Medicine, University of Liverpool, United Kingdom
[e]Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
[f]Department of Clinical Medicine, Aalborg University, Denmark
[g]Brownlow Group GP Practice, Liverpool, United Kingdom

The Lancet Regional Health - Europe 2024;37: 100784
https://doi.org/10.1016/j.lanepe.2023.100784

### Summary

**Modern anticoagulation therapy has dramatically reduced the risk of stroke and systemic thromboembolism in people with atrial fibrillation (AF). However, AF still impairs quality of life, increases the risk of stroke and heart failure, and is linked to cognitive impairment. There is also a recognition of the residual risk of thromboembolic complications despite anticoagulation. Hence, AF management is evolving towards a more comprehensive understanding of risk factors predisposing to the development of this arrhythmia, its' complications and interventions to mitigate the risk. This review summarises the recent advances in understanding of risk factors for incident AF and managing these risk factors. It includes a discussion of lifestyle, somatic, psychological, and socioeconomic risk factors. The available data call for a practice shift towards a more individualised approach considering an increasingly broader range of health and patient factors contributing to AF-related health burden. The review highlights the needs of people living with co-morbidities (especially with multimorbidity), polypharmacy and the role of the changing population demographics affecting the European region and globally.**



Keywords: Atrial fibrillation; Comorbidities; Lifestyle; Risk factors

### Introduction

Management of atrial fibrillation (AF) has been revolutionised by advances in anticoagulation for stroke prevention leading to the widespread use of non-vitamin K antagonist oral anticoagulants (NOACs, sometimes referred to as direct oral anticoagulants, DOACs). There have also been major advances in the field of treating AF with catheter ablation. Despite widespread anticoagulation for stroke prevention, there remains a residual risk of thromboembolic complications despite anticoagulation. Hence, there is the evolution of AF management towards a more holistic or integrated care approach. This review provides an update on the recent advances in understanding and managing risk factors for AF development and its complications, including a discussion of lifestyle, somatic, psychological and socioeconomic risk factors.

DOIs of original articles: https://doi.org/10.1016/j.lanepe.2023.100786, https://doi.org/10.1016/j.lanepe.2023.100785, https://doi.org/10.1016/j.lanepe.2023.100827, https://doi.org/10.1016/j.lanepe.2023.100801, https://doi.org/10.1016/j.lanepe.2023.100797
*Corresponding author. Department of Primary Care and Mental Health, University of Liverpool, United Kingdom.
*E-mail address:* Eduard.Shantsila@liverpool.ac.uk (E. Shantsila).

### Lifestyle factors

Cardiovascular risk factors and concomitant diseases detection and management were emphasized in recent AF guidelines.[1] An unhealthy lifestyle and risk factors could contribute to an increase in the risk of AF, which is typically influenced by the interaction of multiple factors. Recent studies have reported that lifestyle modification, including weight loss, physical activity, and risk factor modification reduce AF burden and symptom severity.

#### Physical activity

Regular physical activity (PA) improves cardiovascular health and is associated with lower incidence, recurrence, and burden of AF and better cardiac function, and quality of life (Table 1, Fig. 1) in AF patients.[2,3] Conversely, a sedentary lifestyle is a risk factor for the development of AF.[4,5] A study of accelerometer-measured PA concluded that patients who adhered to the PA guidelines (performing moderate-to-vigorous

**Key messages**

- A sedentary lifestyle is a risk factor for the development of AF, and high-intensity interval training improves functional capacity and quality of life in AF.
- Obesity increases the risk of AF, whilst weight loss reduces AF recurrence and symptoms.
- There is a linear dose–response relationship between alcohol use and AF risk.
- Hypertension is associated with a 1.7–2.5-fold increased risk of AF, which can be reduced by antihypertensive therapy.
- Diabetes mellitus is associated with a 1.28-fold increased relative risk of incident AF.
- A history of myocardial infarction increases the risk of AF by 60–77%.
- Chronic obstructive pulmonary disease doubles AF risk.
- Men are usually reported to have a 30–70% higher prevalence of AF than women, but the lifelong risk of AF is similar.
- White people more often develop AF than people of South Asian and Black origin.

physical activity ≥150 min/week) had an 18% lower AF incidence.[6] Meanwhile, concerns exist regarding extreme or endurance exercise increasing AF risk. Several studies reported a higher risk of AF in high-endurance athletes whose exercise levels far exceed standard PA recommendations.[7,8] Nonetheless, high-intensity interval training has recently received attention due to its time efficiency, and reduction of AF burden.[9] High-intensity interval training improves functional capacity and quality of life in AF, similar to moderate-to-vigorous continuous training.[10]

Relatively little is known about the benefit of PA in the context of cardiovascular outcomes such as stroke, heart failure (HF), or mortality in patients with AF. Population-level cohort studies have demonstrated that increasing regular PA is inversely related to all-cause and cardiovascular mortality, sudden cardiac death, dementia, and HF (Table 2).[42–46] The benefit of PA for stroke prevention in AF is inconclusive.[11,42,44,47] A mixture of positive and insignificant results with a lack of statistical power might originate from the small number of stroke events in each study, requiring long-term follow-up (Table 3). The less secure benefit of PA on a lower risk of stroke might be explained by the apparent culprit pathology of stroke in AF—left atrial remodelling and reduced function of the left atrial appendage[48]—which is primarily modified by the use of anticoagulants.

A recent systematic review of exercise interventions in AF patients (12 studies, 670 participants) demonstrated improvements in exercise capacity and quality of life, and a decrease in AF burden with exercise.[113] However, the interventions were limited and heterogenous and future research to co-develop interventions to address the needs of the varied AF population, are warranted. A Cochrane review update examining exercise-based cardiac rehabilitation for AF patients to non-exercise comparators (19 trials, 1948 participants) reported a significant reduction in AF symptom severity and burden, and AF episode frequency and duration, and improvement in quality of life with exercise-based cardiac rehabilitation but no difference in overall quality of life, major adverse CV events or death.[114] The quality of the evidence was low and therefore future high-quality RCTs to examine the efficacy of exercise-based interventions for AF patients are needed.

Patients with AF engage in much less PA than patients without AF.[115] The lower participation in PA could be attributed to advanced age and the multimorbid status.[116] Understanding the reasons for this, and the best strategies for PA promotion needs further exploration.

## Obesity

Obesity is a global epidemic and a risk factor for AF development, recurrence, complications after catheter ablation, ischaemic stroke, and death in pre-existing AF.[14,49,50] There are multiple pathophysiological links between obesity and AF (Fig. 2). Conversely, weight loss reduces AF recurrence, burden, and symptoms.[82–84] Although a recent RCT in people with obesity found no benefit from a structured weight reduction program for AF recurrence after catheter ablation, a healthy weight should be promoted in all AF patients.[84]

Several studies have evaluated the impact of weight loss interventions, either focusing on weight loss alone or as a part of multiple risk factor management.[81–83,117] Weight reduction is demonstrated to be associated with lower AF recurrence, burden, duration, and less symptoms.[82–84] Intense weight reduction may improve the profiles of collateral cardiovascular risk factors, thereby contributing to better outcomes in AF. Meanwhile, a recent randomized clinical trial of AF ablation in obese patients demonstrated no difference in AF burden between those with or without a structured weight reduction program.[84] However, a positive effect of BMI reduction on recurrence-free survival in persistent AF was observed, suggesting the importance of weight management as an adjunct to other AF treatment strategies.

## Smoking

Smoking is a major modifiable risk factor for cardiovascular diseases. Epidemiological studies and meta-analyses have reported that smoking, especially current smoking, increases the risk of AF.[16] There is a strong dose–response relationship between current smoking and AF risk, with a weaker dose-dependent risk for previous smoking.[16] Childhood second-hand smoke exposure increases risk of adulthood AF, demonstrating the chronic deleterious effects on AF risk after the first exposure.[118] Smoking increases the risk of all-cause death and cardiovascular death in AF.[52] Promotion of smoking cessation is essential as this lowers the risk of ischaemic stroke, dementia, and reduces mortality in AF.[88,89]

| Study | Country | Predictor | Number of participants | Results risk estimate (95% CI) |
|---|---|---|---|---|
| *Physical activity (sedentary)* | | | | |
| Faselis, 2016[2] | *United States*<br>Veterans Affairs Medical Center, Washington, DC | Physical fitness on exercise tolerance test vs least fit | 5962 | Moderately fit: HR 0.80 (0.67–0.97)<br>Fit: HR 0.55 (0.45–0.68)<br>Highly fit: HR 0.37 (0.29–0.47) |
| Mozaffarian, 2008[4] | *United States*<br>Cardiovascular Health Study | Leisure-time activity vs 1st quintile of activity | 5446 | 3rd quintile: aHR 0.75 (0.61–0.90)<br>4th quintile: aHR 0.78 (0.65–0.95)<br>5th quintile: aHR 0.64 (0.52–0.79) |
| Garnvik, 2018[5] | *Norway*<br>Third Nord-Trøndelag Health study (HUNT 3) | Active vs inactive (in people with obesity) | 43,602 | HR 0.78 (0.55–1.09) |
| Andersen, 2013[7] | *Sweden*<br>Vasaloppet skiers (national registries) | Highest number of completed skiing races vs lower number of skiing races (in endurance skiers) | 52,755 | aHR 1.29 (1.04–1.61) |
| Svedberg, 2019[11] | *Sweden*<br>Vasaloppet skiers (national registries) | Skiers vs non-skiers | 736,102 | Women: HR 0.55 (0.48–0.64)<br>Men: HR 0.98 (0.93–1.03) |
| Jin, 2019[13] | Korea<br>Korean National Health Insurance Service database | WHO recommended physical activity (500–1000 MET min/week) vs inactive | 501,690 | aHR 0.88 (0.80–0.97) |
| *Obesity* | | | | |
| Wong, 2015[14] | Meta-analysis | Effect of 5 kg/m$^2$ BMI increase | 626,603 [51][a] | Cohort studies: OR 1.29 (1.23–1.36)<br>Case-control studies: OR 1.19 (1.13–1.26) |
| *Obstructive sleep apnoea* | | | | |
| Cadby, 2015[15] | *Australia*<br>Sleep clinic registry | Presence vs absence of apnea/hypopnea index (AHI) > 5/h | 6841 | aHR 1.55 (1.21–2.00) |
| *Smoking* | | | | |
| Aune, 2018[16] | Meta-analysis | Smoking vs no smoking | Current smokers 388,030 [11][a]<br>Former smokers 372,229 [9][a] | Current smokers: RR 1.32 (1.12–1.56)<br>Former smokers: RR 1.09 (1.00–1.18) |
| *Alcohol* | | | | |
| Larsson, 2014[17] | Meta-analysis | Drinks/week (12 g alcohol/drink) vs < 1 drink/week | 79,019 | 1–6 drinks: aRR 1.01 (0.94–1.09)<br>7–14 drinks: aRR 1.07 (0.98–1.17)<br>15–21 drinks: aRR 1.14 (1.01–1.28)<br>>21 drinks: aRR 1.39 (1.22–1.58) |
| *Caffeine* | | | | |
| Shen, 2011[18] | United States<br>The Framingham Heart Study | Caffeine consumption vs lowest quartile | 4526 | Quartile 2: HR 0.84 (0.62–1.15)<br>Quartile 3: HR 0.87 (0.64–1.20)<br>Quartile 4: HR 0.98 (0.70–1.39) |
| Conen, 2010[19] | *United States*<br>Women's Health Study | Caffeine consumption vs lowest quintile | 33,638 | Quintile 2: aHR 0.88 (0.72–1.06)<br>Quintile 3: aHR 0.78 (0.64–0.95)<br>Quintile 4: aHR 0.96 (0.79–1.16)<br>Quintile 5: aHR 0.89 (0.73–1.09) |
| Cheng, 2014[20] | Meta-analysis | Caffeine consumption vs no consumption | 228,465 | Any consumption: RR 0.90 (0.81–1.01)<br>Low consumption: RR 0.89 (0.80–0.99)<br>High consumption: RR 0.84 (0.75–0.94) |
| Bazal, 2021[21] | *Spain*<br>'Seguimiento Universidad de Navarra' (SUN) and 'Prevención con Dieta Mediterránea' (PREDIMED) cohorts | Moderate coffee intake (1–7 cups/week) vs no intake | 25,462 | HR 0.60 (0.44–0.82) |
| Bodar, 2019[22] | *United States*<br>Physicians' Health Study | coffee consumption (cup/week) vs rarely/never | 18,960 | ≤1 cup: aHR 0.85 (0.71–1.02)<br>1 cup: aHR 0.85 (0.74–0.98)<br>2–4 cups: aHR 1.07 (0.88–1.30)<br>5–6 cups: aHR 0.93 (0.74–1.17) |
| *Hypertension* | | | | |
| Rattani, 2019[23] | Atherosclerosis Risk in Communities (ARIC) | Hypertension vs no hypertension | 14,915 | aHR 1.44 (1.32–1.56) |
| Lee, 2021[24] | *Korea*<br>Korean National Health Insurance Service database | Hypertension burden category (incremental burden) vs no hypertension | 3,726,172 | Category 1: aHR 1.13 (1.07–1.19)<br>Category 2: aHR 1.29 (1.23–1.36)<br>Category 3: aHR 1.41 (1.35–1.49)<br>Category 4: aHR 1.46 (1.39–1.53) |

(Table 1 continues on next page)

| Study | Country | Predictor | Number of participants | Results risk estimate (95% CI) |
|---|---|---|---|---|
| (Continued from previous page) | | | | |
| *Lipids* | | | | |
| Mora, 2014[25] | *United States* | LDL cholesterol highest versus lowest quintile | 23,738 | aHR 0.72 (0.56–0.92) |
| Watanabe, 2011[29] | *Japan* | Low vs normal HDL cholesterol | 28,449 | Women: aHR 2.86 (1.49–5.50)<br>Men: aHR 1.35 (0.77–2.38) |
| Ding, 2022[26] | *Sweden*<br>Swedish Apolipoprotein-Related Mortality Risk (AMORIS) cohort | Total cholesterol >5.17 mmol/L<br>LDL cholesterol >3.34 mmol/L | 65,136 | aHR 0.64 (0.45–0.92)<br>aHR 0.61 (0.41–0.99) |
| *Diabetes mellitus* | | | | |
| Aune, 2018[27] | Meta-analysis | Diabetes vs no diabetes | 464,229 [32][a] | RR 1.30 (1.03–1.66) |
| *Benjamin, 1994*[141] | *United States*<br>Framingham Heart Study | Diabetes vs no diabetes | 4731 | OR 2.1 (1.5–2.8) |
| Lee, 2017[28] | *Korea*<br>Korean National Health Insurance Service database | Combined risk factors (IFG + prehypertension) vs no risk | 366,507 | HR 1.27 (1.05–1.54) |
| *COPD* | | | | |
| Grymonprez, 2019[30] | *The Netherlands*<br>Rotterdam Study population-based cohort | COPD vs no-COPD<br>COPD with frequent exacerbations vs no COPD | 10,943 | aHR 1.28 (1.04–1.57)<br>aHR 1.99 (1.42–2.79) |
| *CKD* | | | | |
| Nelson, 2012[31] | *United States*<br>Medicare database | CKD vs no CKD (end-stage CKD excluded) | 55,962 | Stage 1–2: aHR 1.02 (0.94–1.11)<br>Stage 3–5: aHR 1.13 (1.09–1.18) |
| Baber, 2011[37] | *United States*<br>Reasons for Geographic and Racial Differences in Stroke (REGARDS) study | CKD vs no CKD | 26,917 | Stage 1–2: aOR 2.67 (2.04–3.48)<br>Stage 3: aOR 1.68 (1.26–2.24)<br>Stage 4–5: aOR 3.52 (1.73–7.15) |
| *Ethnicity* | | | | |
| Almulhem, 2021[33] | *United Kingdom*<br>Health Improvement Network (THIN) database | South Asian vs White ethnicity | 284,610 | aHR 0.53 (0.48–0.59) |
| Aurelius, 2023[285] | *United Kingdom*<br>UK arm of a prospective repository of people with ischaemic stroke | South Asian vs. White ethnicity | 3515 | OR 0.40 (0.33–0.49) |
| *Mental health* | | | | |
| Ahn, 2022[36] | *Korea*<br>Korean National Health Insurance Database | Mental disorder (depression, insomnia, anxiety, bipolar disorder or schizophrenia) vs no mental disorder | 6,576,582 | aHR 1.53 (1.44–1.62) |
| Bae, 2022[218] | *Korea*<br>Korean National Health Insurance Database | Mental disorder (depression, insomnia, anxiety, bipolar disorder or schizophrenia) vs no mental disorder | 2,512,690 | aHR 1.19 (1.17–1.21) |
| Chou, 2017[221] | *Taiwan*<br>National Health Insurance Database | Exposure to antipsychotic drugs vs no exposure | 68,972 | aOR 1.17 (1.10–1.26) |
| Du, 2022[39] | Systematic review | Anxiety vs no anxiety | 549 [5][a] | aRR 2.36 (1.71–3.26) |
| Feng, 2020[220] | *Norway*<br>Third Nord-Trøndelag Health study (HUNT 3) | Anxiety or depression vs no anxiety or depression | 37,402 | Mild-moderate anxiety: aHR 1.1 (0.9–1.5)<br>Severe anxiety: aHR 1.0 (0.8–1.4)<br>Mild-moderate depression: aHR 1.5 (1.2–1.8)<br>Severe depression: aHR 0.9 (0.6–1.3) |
| Fransson, 2018[60] | *Sweden*<br>Swedish Longitudinal Occupational Survey of Health (SLOSH) | Job strain vs no job strain | 13,477 | aHR 1.48 (1.00–2.18) |
| Graff, 2017[41] | *Denmark*<br>Danish National Health Survey | Highest vs lowest quintile of perceived stress | 114,337 | HR 1.01 (0.88–1.16) |
| Wu, 2022[219] | Meta-analysis | Anxiety<br>Anger<br>Depression<br>Work stress | 21,791 [3][a]<br>21,791 [3][a]<br>5,160,247 [6][a]<br>51,664 [4][a] | HR 1.10 (1.02–1.19)<br>HR 1.15 (1.04–1.26)<br>HR 1.25 (1.12–1.39)<br>HR 1.18 (1.05–1.32) |

aHR, adjusted hazard ratio; aOR, adjusted odds ratio; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; HDL: high density lipoproteins; HR, hazard ratio; LDL: low density lipoproteins; MMSE, mini mental state examination; OAC, oral anticoagulation; OR, odds ratio; RD, risk difference; RR, relative risk; SEE, systemic embolic events; UD, use difference. [a]Number of studies in a meta-analysis.

***Table 1:*** **Risk factors for the development of atrial fibrillation.**




***Fig. 1:*** Factors associated with incident atrial fibrillation.

## Alcohol

Alcohol consumption is a well-established risk factor for AF. Although the exact mechanism by which alcohol causes AF is not fully understood, alcohol has a direct effect on the atrium (myocyte injury, inflammation, and fibrosis) and autonomic modulation (sympathetic activation and vagal inhibition), which shorten the atrial action potential and atrial effective refractory period and in turn promote initiation and maintenance of AF.[119] While moderate-high alcohol consumption clearly increases AF risk, effects of low alcohol intake is controversial.[17] A linear rather than a J-shaped dose–response relationship was reported by a meta-analysis.[17] Regarding particular alcoholic beverages, drinking wine and liquor but not beer was related to higher AF risk.[17] In addition to direct cardiac effects (e.g., cardiomyopathy), alcohol could worsen AF risk factor profile, including obesity, hypertension, and OSA.

Moderate-heavy alcohol consumption is associated with an increased risk of progression from paroxysmal AF to persistent AF.[53] After catheter ablation, daily alcohol consumption is associated with unfavourable atrial remodelling and AF recurrence.[54,55] Heavy alcohol consumption (>27 standard drinks/week) increases the risk of thromboembolism and mortality in AF, but moderate consumption may lower risk of ischaemic stroke.[56] However, a recent observational study reported an increased risk of ischaemic stroke in patients with newly diagnosed AF irrespective of the amount of alcohol they consumed.[58]

Alcohol abstinence reduces risk of new AF[90] and its recurrence after catheter ablation.[55] A recent RCT found that alcohol abstinence for 6 months reduced AF recurrence and burden, and improved AF-related quality of life in patients with AF who previously drank ≥10 drinks/week.[92] Furthermore, abstinence from alcohol following a diagnosis of AF may lower the risk of composite outcome and an ischaemic stroke.[57,58]

## Caffeine

Coffee is widely consumed worldwide, and a rich source of caffeine. Sympathetic activation could promote AF.[120] However, the antiarrhythmic properties of caffeine include the non-selective inhibition of adenosine receptors and antioxidant properties.[121,122] The net effects of caffeine consumption on AF risk have been debated. Large-scale observational studies, such as the Framingham Heart Study and the Women's Health Study, have found no relationship between chronic caffeine consumption and AF.[18,19] Several meta-analyses reported that caffeine exposure did not increase the risk of AF, or even reduced it.[20] Two recent prospective cohort studies showed that moderate coffee consumption (1–7 cups/week) lowered AF risk.[21,22] Also, even high caffeine

| Study | Country | Predictor | Outcomes | Number of patients | Results risk estimate (95% CI) |
|---|---|---|---|---|---|
| *Exercise* | | | | | |
| Garnvik, 2020[42] | *Norway*<br>Third Nord-Trøndelag Health study (HUNT 3) | Active (adherence to physical activity guidelines) vs inactive (self-reported) | Death<br>CV death<br>CV disease<br>Stroke | 1117 | HR 0.55 (0.41–0.75)<br>HR 0.54 (0.34–0.86)<br>HR 0.78 (0.58–1.04)<br>HR 0.70 (0.42–1.15) |
| Proietti, 2017[43] | *European region*<br>EURObservational Research Programme on AF<br>(EORP-AF) General Registry | Regular or intense physical activity vs inactive (self-reported) | Stroke or TIA<br>Bleeding<br>CV death or TE or bleeding | 2442 | *Regular activity:*<br>OR 0.35 (0.07–1.62)<br>OR 0.75 (0.47–1.19)<br>OR 0.40 (0.26–0.63)<br>*Intense activity:*<br>OR 0.83 (0.10–6.65)<br>OR 0.49 (0.17–1.37)<br>OR 0.29 (0.10–0.80) |
| Ahn, 2021[44] | *Korea*<br>Korea National Health Insurance Service database | New exercisers and exercise maintainers vs non-exercisers | Ischaemic stroke<br>HF<br>Death | 66,692 | *New exercisers:*<br>HR 0.90 (0.79–1.03)<br>HR 0.95 (0.90–0.99)<br>HR 0.82 (0.73–0.91)<br>*Exercise maintainers:*<br>HR 0.86 (0.77–0.96)<br>HR 0.92 (0.88–0.96)<br>HR 0.61 (0.55–0.67) |
| Dai, 2022[47] | *United States*<br>Systemic Assessment of Geriatric Elements in AF<br>(SAGE-AF) study | Active (adherence to physical activity guidelines) vs inactive (self-reported) | Death<br>Stroke<br>Major bleeding | 1244 | aHR 0.60 (0.38–0.95)<br>aHR 1.44 (0.50–4.09)<br>aHR 0.86 (0.56–1.32) |
| *Obesity* | | | | | |
| Wong, 2015[14] | Meta-analysis | Effect of 5 kg/m2 BMI increase | Post-operative and post-ablation AF | 626,603 [51][a] | *Cohort studies:*<br>OR 1.10 (1.04–1.17)<br>*Case-control studies*<br>OR 1.13 (1.06–1.22) |
| Tonnesen, 2022[49] | *Denmark*<br>Danish nationwide registers | Increased vs normal weight | Recurrent AF post catheter ablation | 9188 | *Overweight:*<br>HR 1.15 (1.07–1.23)<br>*Obese:*<br>HR 1.18 (1.09–1.28)<br>*Morbidly obese:*<br>HR 1.26 (1.13–1.41) |
| Overvad, 2013[50] | *Denmark*<br>Danish Diet, Cancer and Health study | Increased vs normal weight | Ischaemic stroke or TE or death | 57,053 | *Overweight:*<br>HR 1.31 (1.09–1.56)<br>*Obese:*<br>HR 1.55 (1.27–1.90) |
| *Obstructive sleep apnoea* | | | | | |
| Holmqvist, 2015[51] | United States<br>Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) | OSA vs no OSA | Hospitalisation<br>Death<br>CV death or MI or stroke or TIA<br>Major bleeding | 10,132 | HR 1.12 (1.03–1.22)<br>HR 0.94 (0.77–1.15)<br>HR 1.07 (0.85–1.34)<br>HR 1.18 (0.96–1.46) |
| *Smoking* | | | | | |
| Zhu, 2016[52] | Meta-analysis | Smoking vs no smoking | Death<br>CV death<br>Stroke or TE<br>Major bleeding | 87,373 [8][a] | RR 1.82 (1.33–2.49)<br>RR 1.54 (1.31–1.81)<br>RR 1.19 (0.97–1.46)<br>RR 1.93 (1.08–3.47) |
| *Alcohol* | | | | | |
| Ruigomez, 2005[53] | *United Kingdom*<br>General Practice Research Database (GPRD) | Moderate-high alcohol consumption vs lower or no consumption | Progression to permanent AF | 525 | OR 3.0 (1.1–8.0) |
| Qiao, 2015[54] | *China* | Alcohol consumption vs no consumption | AF recurrence after catheter ablation | 122 | aHR 1.58 (1.09–2.30) |
| Takigawa, 2016[55] | *Japan* | Risk per 1 day/week increase in alcohol consumption | AF recurrence after catheter ablation | 1361 | HR 1.07 (1.00–1.15, p = 0.04) |

(Table 2 continues on next page)

| Study | Country | Predictor | Outcomes | Number of patients | Results risk estimate (95% CI) |
|---|---|---|---|---|---|
| (Continued from previous page) | | | | | |
| Overvad, 2013[56] | Denmark<br>The Danish Diet, Cancer and Health study | ≥14 drinks/week vs < 14 drinks/week | TE<br>Death | 57,053 | 14–20 drinks/week aHR 0.72 (0.39–1.33)<br>aHR 1.08 (0.79–1.49)<br>21–27 drinks/week: aHR 1.08 (0.65–1.80)<br>aHR 1.10 (0.80–1.52)<br>>27 drinks/week aHR 1.02 (0.68–1.54)<br>aHR 1.51 (1.20–1.89) |
| Lim, 2021[57] | *Korea* | Heavy alcohol consumption vs abstainers | Composite adverse outcomes | 9411 | aHR 1.32 (1.06–1.66) |
| Lee, 2021[58] | *Korea*<br>Korean nationwide claims and health examination database | Non-drinkers vs current drinkers (per 1000 person-years) | Ischaemic stroke | 97,869 | Adjusted incidence rate differences<br>−2.98 (−3.81 to −2.15) |
| *Hypertension* | | | | | |
| Vemulapalli, 2016[59] | *International*<br>ROCKET-AF trial | Effect of 10 mm Hg increase in screening SBP<br>Hypertension vs no hypertension | Stroke or TE | 14,256 | Effect of 10 mm Hg increase<br>HR 1.07 (1.02–1.13)<br>Controlled hypertension<br>HR 1.22 (0.89–1.66)<br>Uncontrolled hypertension<br>HR 1.42 (1.03–1.95) |
| Rao, 2015[136] | *International*<br>ARISTOTLE trial | Hypertension vs no hypertension | Stroke or TE<br>Haemorrhagic stroke<br>Ischaemic stroke<br>Major bleeding | 18,201 | HR 1.53 (1.25–1.86)<br>HR 1.85 (1.26–2.72)<br>HR 1.50 (1.18–1.90)<br>HR 0.80 (0.66–0.98) |
| Kim, 2018[61] | *Korea*<br>Korean nationwide claims and health examination database | Hypertension vs no hypertension | Major cardiovascular events, ischaemic stroke, intracranial haemorrhage | 298,374 | MACE<br>HR 1.12 (1.09–1.14)<br>Stroke<br>HR 1.16 (1.12–1.20)<br>ICH<br>HR 1.27 (1.17–1.39) |
| Kim, 2019[62] | *Korea*<br>Korean nationwide claims and health examination database | Increase of hypertension duration vs no hypertension | Ischaemic stroke | 245,459 | 0–3 years<br>HR 1.32 (1.23–1.41)<br>3–5 years<br>HR 1.50 (1.38–1.63)<br>≥5 years<br>HR 1.51 (1.39–1.65) |
| Kim, 2020[63] | *Korea*<br>Korean nationwide claims and health examination database | Optimal BP (120–129/80–84 mmHg) vs non-optimal BP (≥140/90 mmHg) | Overall dementia<br>Vascular dementia | 171,228 | Overall dementia<br>HR 1.07 (1.01–1.13)<br>Vascular dementia<br>HR 1.23 (1.08–1.39) |
| *Diabetes mellitus* | | | | | |
| Anselmino, 2015[64] | Meta-analysis | Raised basal glycated haemoglobin | AF recurrence after catheter ablation | 1464 [15][a] | Regression coefficient 0.5 (0.1–0.9, p = 0.001) |
| Proietti, 2016[67] | *Nine European Countries*<br>EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry (EORP-AF survey) | Diabetes vs no diabetes | CV death TE | 3086 | aOR 2.30 (1.40–3.80)<br>NS (values not provided) |
| *Coronary artery disease* | | | | | |
| Proietti, 2016[67] | *Nine European Countries*<br>EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry (EORP-AF survey) | CAD vs no CAD | TE<br>CV death | 3086 | aOR 3.54 (2.24–5.59)<br>NS (values not provided) |

(Table 2 continues on next page)

| Study | Country | Predictor | Outcomes | Number of patients | Results risk estimate (95% CI) |
|---|---|---|---|---|---|
| (Continued from previous page) | | | | | |
| *Heart failure* | | | | | |
| Uhm, 2021[66] | *Korea*<br>Multicentre, prospective, registry—CODE-AF (COmparison study of Drugs for symptom control and complication prEvention of AF) | - HF with preserved EF<br>- HF with mid-range EF<br>- HF with reduced EF<br>vs no HF | Stroke or TE<br>Major bleeding | 10,780 | *HF with preserved EF:*<br>aHR 3.19 (1.04–9.81)<br>aHR 4.12 (0.46–36.95)<br>*HF with mid-range EF:*<br>aHR 0.81 (0.18–3.62)<br>No data<br>*HF with reduced EF:* aHR 1.26 (0.34–4.72)<br>aHR 1.22 (0.08–19.62) |
| Proietti, 2016[67] | *Nine European Countries*<br>EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry (EORP-AF survey) | HF vs no HF | CV death<br>TE | 3086 | aOR 9.90 (4.48–21.88)<br>NS (values not provided) |
| *Chronic obstructive pulmonary disease* | | | | | |
| Rodriguez-Manero, 2019[192] | *Spain*<br>Data warehouse of the Galician Healthcare Service | COPD vs no COPD | Death<br>TE<br>Bleeding | 7990 | aHR 1.92 (1.54–2.40)<br>NS (no values not provided) aHR 1.72 (1.16–2.54) |
| Hirayama, 2018[68] | *United States* | Acute exacerbation of chronic obstructive pulmonary disease vs no acute exacerbation | AF-related emergency department visits or hospitalisations | 944 | RR 1.93 (1.63–2.29) |
| Proietti, 2016[67] | *Nine European Countries*<br>EURObservational Research Programme Pilot Survey on Atrial Fibrillation Registry (EORP-AF survey) | COPD vs no COPD | CV death<br>TE | 3086 | aOR 2.03 (1.15–3.58)<br>NS (values not provided) |
| *Chronic kidney disease* | | | | | |
| Ocak, 2022[69] | *Netherlands*<br>The Utrecht Cardiovascular Cohort Second Manifestation of Arterial disease (UCC-SMART) cohort | Combination of CKD with AF, vs CKD or AF alone | Bleeding<br>Ischaemic stroke<br>Death | 12,394 | RERI 0.62 (−0.75–1.99)<br>RERI 1.88 (0.31–3.46)<br>RERI 0.34 (−0.12–0.81) |
| Nelson, 2012[31] | *United States*<br>Medicare database | CKD (excluding end-stage CKD) vs no CKD | Death | 55,962 | *Stage 1–2:* aHR 1.14 (1.00–1.30)<br>*Stage 3–5:* aHR 1.27 (1.20–1.35) |
| Guo, 2013[76] | China | eGFR ≤60 vs eGFR >60 | Death<br>Ischaemic stroke<br>Major bleeding | 617 | aHR 1.78 (1.01–3.11)<br>aHR 1.45 (0.69–3.02)<br>aHR 0.95 (0.35–2.56) |
| *Cognitive decline or dementia* | | | | | |
| Nagata, 2023[231] | *Japan*<br>All Nippon AF In the Elderly (ANAFIE) Registry | Cognitive decline (>2 MMSE points) | Death<br>Stroke or TE<br>Major bleeding | 2963 | HR 1.96 (1.11–3.47)<br>HR 0.97 (0.57–1.65)<br>HR 1.61 (0.79–3.26) |
| *Frailty* | | | | | |
| Proietti, 2022[75] | Meta-analysis | Frailty vs no frailty | Death<br>Ischaemic stroke<br>Bleeding | 1,187,651 [33][a] | OR (3.46–8.94)<br>OR (1.00–2.52)<br>OR. (1.11–2.41) |
| He, 2022[251] | Meta-analysis | Frailty vs no frailty | Death<br>Major bleeding | 97,413 [10][a] | RR 2.77 (1.68–4.57)<br>RR 1.83 (1.24–2.71) |
| Wilkinson, 2021[255] | *England*<br>384 general practices | Severe frailty vs no frailty | All-cause death<br>Gastrointestinal bleeding<br>Falls<br>Stroke | 536,955 | aHR 4.09 (3.43–4.89)<br>aHR 2.17 (1.45–3.25)<br>aHR 8.03 (4.60–14.0)<br>aHR 1.67 (1.48–1.88) |
| Wilkinson, 2020[257] | *Multiple countries*<br>Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial | Frailty (for each 0.1 increase in the frailty index) | Stroke or TE<br>Major bleeding | 20,867 | aHR 1.37 (1.19–1.58)<br>aHR 1.42 (1.27–1.59) |
| Wilkinson, 2019[253] | Meta-analysis | Frailty vs no frailty | Stroke or death | 1321 [3][a] | aOR 0.45 (0.22–0.93) |

(Table 2 continues on next page)

| Study | Country | Predictor | Outcomes | Number of patients | Results risk estimate (95% CI) |
|---|---|---|---|---|---|
| (Continued from previous page) | | | | | |
| Perera, 2009[80] | Australia | Frailty vs no frailty | Death<br>Embolic stroke<br>Major haemorrhage | 207 (acute admission) | RR 2.8 (1.2–6.5)<br>RR 3.5 (1.0–12.0)<br>RR 1.5 (0.7–3.0) |
| Madhavan, 2019[71] | *United States*<br>Outcomes Registry for Better Informed Care in AF (ORBIT AF) | Frailty vs no frailty | Death | 9749 | HR 1.29 (1.08–1.55) |
| *Mental health disorders* | | | | | |
| Farran, 2022[224] | Meta-analysis | Serious mental disorders vs no serious disorders | Stroke<br>Major bleeding | 220,014 [3][a]<br>120,757 [3][a] | HR 1.09 (0.85–1.40)<br>HR 1.11 (0.95–1.28) |
| Sogaard, 2017[226] | *Denmark*<br>Nationwide Danish Health Registry | Schizophrenia<br>Severe depression<br>Bipolar disease vs none of the above | Ischaemic stroke | 534<br>400<br>569 matched 1:5 to people without mental disorders | HR 1.37 (0.88–2.14)<br>HR 1.36 (0.89–2.08)<br>HR 1.04 (0.69–1.56) |

AF, atrial fibrillation; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; EF, ejection fraction; HF, heart failure; HR, hazard ratio; MMSE, mini mental state examination; OAC, oral anticoagulation; OR, odds ratio; OSA, obstructive sleep apnoea; RD, risk difference; RERI: relative excess risk due to interaction; RR, relative risk; SBP, systolic blood pressure; TE, thromboembolic events; TIA, transient ischaemic attack. [a]Number of studies in a meta-analysis.

***Table 2:*** **Effect of risk factors on outcomes in atrial fibrillation.**

intake (>320 mg/day) was associated with a lower AF risk.[123] Overall, current data do not describe moderate coffee consumption as a risk for AF.

## Comorbidities

The risk of AF and its complications can be amplified by comorbidities that interfere with the pathogenesis of the arrhythmia. The contributing mechanisms vary and depend on the nature of the comorbidities, including effects on intracardiac haemodynamics, inflammation, hypoxia and metabolic changes.

### Obstructive sleep apnoea

OSA, the most common form of sleep-disordered breathing, is common in AF (prevalence 21–74%).[124,125] Intermittent nocturnal hypoxemia or hypercapnia, oscillations in intrathoracic pressure, sympathovagal imbalance, oxidative stress, and systemic inflammation driven by OSA results in the development of a prothrombotic state, atrial fibrosis, and electrical remodeling.[126] OSA increases the risk of AF, and a Mendelian randomization study has confirmed the causal effect.[127] OSA is also associated with the recurrence of AF after electrical cardioversion or catheter ablation, and there is a dose–response relationship between OSA severity and AF incidence and burden.[15] In contrast, continuous positive airway pressure may reduce the incidence, progression, recurrence, and symptoms of AF.[51,86,128] Considering OSA's causal and prognostic effect on AF, screening for OSA in patients with AF should be considered as part of lifestyle modification and treatment strategies.[82,129]

### Hypertension

Hypertension is a well-known risk factor for AF and is associated with a 1.7–2.5-fold increased risk of developing AF.[130] The risk of developing AF is particularly high in poorly controlled hypertension.[131] Multivariate analyses from the Atherosclerosis Risk in Communities (ARIC) study reported the risk of development of AF was 1.44-fold higher in people with hypertension, particularly in women who had 1.55-fold higher risk vs. men.[23] There is increasing focus on the dynamic nature of the risk associated with hypertension burden over time and high visit-to-visit variability in BP (a measure of BP control over follow up) which have been associated with AF risk.[24,132,133]

Among people with known AF, hypertension is the most prevalent risk factor, with 1 in 6 cases of AF attributable to hypertension.[134] Identifying new or uncontrolled BP in patients with AF and optimising pharmacological and lifestyle measures to control BP is a key component of the 'C' (cardiovascular and comorbidity) part of the ABC pathway for AF.[135] Left untreated, hypertension results in renal impairment and left ventricular hypertrophy which further increases the risk of AF and its complications.[1] Uncontrolled BP increases both the risk of stroke (ischaemic and haemorrhagic) and the risk of major bleeding associated with oral anticoagulation, as demonstrated in the sub-group analyses of the NOAC trials in AF.[59,62,63,136,137] The Blood Pressure Lowering Treatment Trialists' Collaboration individual patient data meta-analysis demonstrated a significantly lower risk of major adverse cardiovascular events (MACE) and stroke associated with blood pressure lowering drugs in patients with AF at baseline but no difference in cardiovascular or all-cause mortality, over a median 4.5 year follow-up period (Table 3).[93] Therefore, detection of hypertension and control of BP are paramount to prevent development of AF and in those with AF, to optimise management and reduce adverse events.

| Study | Country | Treatment | Outcomes | Number of patients | Results risk estimate (95% CI) | Level of evidence |
|---|---|---|---|---|---|---|
| *Physical activity* | | | | | | |
| Mozaffarian, 2008[4] | US | Low- vs. moderate vs. high-intensity exercise | Incident AF | 5446 | Moderate-intensity exercise: HR 0.72 (0.58–0.89) High-intensity exercise: HR 0.87 (0.64–1.19) | Prospective, Observational cohort study |
| Azarbal, 2014[85] | US | Total weekly physical activity (MET-h/week) | Incident AF | 93,676 | Exercise >9 vs. 0 MET-h/week: HR 0.90 (0.85–0.96) | Prospective, Observational cohort study |
| Garnvik, 2018[5] | Norway | High level of physical activity in obese patients | Incident AF | 43,602 | HR 1.53 (1.03–2.28) in active HR 1.96 (1.44–2.67) in inactive | Prospective, Observational cohort study |
| *Obesity* | | | | | | |
| Abed, 2013[81] | Australia | Physician-led multiple risk factor (weight loss, OSA, hypertension, tobacco, alcohol, and glycemic control) modification clinic | AF symptom burden and severity | 150 | Greater reduction in AF symptom burden scores (11.8 and 2.6 points, P < 0.001), symptom severity scores (8.4 and 1.7 points, P < 0.001) in the intervention group compared with the control group | RCT |
| Pathak, 2014[82] | Australia | Weight loss target BMI <27 kg/m$^2$ or >10% weight loss | Recurrent AF after AF ablation | 149 | HR 4.8 (2.04–11.4) | Prospective, Observational cohort study |
| Pathak, 2015[83] | Australia | Goal-directed weight loss: - 3–9% weight loss - <3% weight loss compared to weight loss ≥10% | AF burden as determined by symptom burden and AF freedom | 355 | weight loss 3–9%: HR 2.0 (1.4–2.9) weight loss <3%: HR 3.0 (2.0–4.3) | Prospective, Observational cohort study |
| Gessler, 2021[84] | Germany | weight-reduction | AF burden between 3 and 12 months after AF ablation | 133 | OR 1.14 (0.37–3.61) | RCT (SORT-AF) |
| *Obstructive sleep apnoea* | | | | | | |
| Patel, 2010[87] | US | Continuous positive airway pressure | AF recurrence after AF ablation | 640 | HR 0.17 (0.08–0.36) | Retrospective, observational |
| Qureshi, 2015[86] | Multiple countries | Continuous positive airway pressure | incident AF | [8][a] | Pooled RR 0.58 (0.47–0.70) | Meta-analysis |
| Hunt, 2022[91] | Norway | Continuous positive airway pressure | AF recurrence after AF ablation | 83 | OR 1.0 (0.4–2.4) | RCT |
| *Smoking* | | | | | | |
| Lee, 2021[88] | Korea | Smoking cessation | Incident ischaemic stroke and all-cause death in AF patients | 97,637 | ischaemic stroke: HR 0.70 (0.60–0.83) all-cause death: HR 0.84 (0.75–0.95) | Observational study |
| Lee, 2022[89] | Korea | Smoking cessation | Incident dementia in AF patient | 126,252 | HR 0.83 (0.72–0.95) | Observational study |
| *Alcohol* | | | | | | |
| Dixit, 2017[90] | US | Alcohol cessation | Incident AF | 15,222 | HR per decade 0.80 (0.72–0.89) | Prospective, Observational cohort study |
| Takahashi, 2021[94] | Japan | Alcohol cessation | AF recurrence after AF ablation | 3474 | Alcohol reduction ≥1%: HR 0.63 (0.52–0.77) | Prospective, Observational cohort study |
| Voskoboinik, 2020[92] | Australia | Alcohol abstinence | freedom from recurrence of AF | 140 | HR 0.55 (0.36–0.84) | RCT |
| Lee, 2021[58] | Korea | Alcohol abstinence | incident ischaemic stroke in AF patient | 97,869 | HR 0.86 (0.77–0.96) | Observational study |
| *Hypertension* | | | | | | |
| Pinho-Gomes, 2021[93] | Multiple countries Blood Pressure Lowering Treatment Trialists' Collaboration | BP-lowering drugs versus placebo in patients with AF recorded at baseline | Composite endpoint: stroke, IHD, or HF Stroke CV death All-cause mortality | 188,570 [22][a] 13,266 (7%) had AF at baseline | 5-mm Hg SBP reduction: Composite: HR 0.91 (0.83–1.00) Stroke: HR 0.83 (0.71–0.96) CV death: HR 0.92 (0.80–1.03) ACM: HR 1.01 (0.91–1.10) | Individual patient data meta-analysis |
| Emdin, 2015[98] | Multiple countries | BP-lowering drugs vs no BP-lowering treatment | Incident AF | 214,763 [27][a] | RR 0.90 (0.86–0.94) | Meta-analysis of RCTs |

(Table 3 continues on next page)

| Study | Country | Treatment | Outcomes | Number of patients | Results risk estimate (95% CI) | Level of evidence |
|---|---|---|---|---|---|---|
| (Continued from previous page) | | | | | | |
| *Diabetes mellitus* | | | | | | |
| Dublin 2010[95] | USA | Pharmacological treatment of DM | Incident AF (treated DM vs. no-DM)<br>Effect of DM treatment on incident AF (per additional 1 year of duration)<br>Duration of DM on incident AF (DM vs. no DM)<br>≤5 years<br>>5 but ≤10 years<br>>10 years | 1410 with AF<br>2203 controls without AF | aOR 1.40 (1.15–1.71)<br>aOR 1.03 (1.01–1.06)<br>aOR 1.07 (0.75–1.51)<br>aOR 1.51 (1.05–2.16)<br>aOR 1.64 (1.22–2.20) | Population based case–control |
| Larsson, 2018[96] | Sweden | Pharmacological DM treatment | Incident AF<br>Incident AF (only for ≥20 years DM duration) | 71,483 | HR 1.01 (0.91–1.12)<br>HR 1.44 (1.02–2.04) | Two population based prospective cohorts |
| Huxley, 2012 ARIC study[97] | USA | Pharmacological DM treatment | Incident AF | 13,025 | aHR 1.35 (1.14–1.60) | Prospective cohort study |
| Chang, 2014[144] | Taiwan | Metformin vs. no DM drugs | Incident AF | 645,710 | aHR 0.81 (0.76–0.86) | National Health Insurance Research Database |
| Chao, 2012[100] | Taiwan | Thiazolidinediones vs. no thiazolidinediones | Incident AF | 12,065 | aHR 0.69 (0.49–0.61) | National Health Insurance Research Database |
| Zhang, 2017[99] | Multiple countries | Thiazolidinediones vs. no thiazolidinediones | Incident AF | 130,854 [7, 3 RCTs, 4 cohorts][a] | OR 0.73 (0.62–0.87) | Meta-analysis |
| *Coronary artery disease* | | | | | | |
| Hiraya, 2019[101] | Japan | CAD vs. no CAD as modifiers of catheter ablation outcomes | Recurrence of AF after AF ablation | 681 | HR 1.45 (1.05–1.97) | Observational study |
| Kornej, 2015[103] | Germany | CAD vs. no CAD as modifiers of catheter ablation outcomes | Recurrence of AF after AF ablation | 1310 | OR 0.87 (0.6–1.25) | Observational study |
| *Heart failure* | | | | | | |
| Marrouche, 2018[102] | Multiple countries | AF ablation vs.pharmacological therapy in patients with HF | Composite: death, unplanned hospitalisation for HF | 363 | HR 0.62 (0.43–0.87) | RCT (CASTLE-AF) |
| Packer, 2021[106] | Multiple countries | AF ablation vs. pharmacological therapy in patients with HF | Composite: death, disabling stroke, serious bleeding, or cardiac arrest Death | 778 | HR 0.64 (0.41–0.99)<br>HR 0.57 (0.33–0.96) | Subanalysis of RCT (CABANA) |
| Rillig, 2021[104] | Multiple countries | Rhythm vs rate control in patients with HF | Composite: cardiovascular death, stroke, hospitalisation for worsening of HF or acute coronary syndrome | 798 | HR 0.74 (0.56–0.97) | Subanalysis of RCT (EAST-AFNET 4) |
| Yang, 2021[105] | Korea | AF ablation vs.pharmacological therapy in patients with HF | Death<br>Cardiovascular death<br>hospitalisation for HF<br>Stroke/systemic embolism | 3173 | HR 0.42 (0.27–0.65)<br>HR 0.38 (0.32–0.62)<br>HR 0.39 (0.33–0.46)<br>HR 0.44 (0.37–0.53) | Observational study |
| Asad, 2019[107] | Multiple countries | AF ablation vs.pharmacological therapy in patients with HF | Death<br>Cardiovascular admission<br>Atrial arrhythmia | 4464 [18][a] | RR 0.52 (0.35–0.76)<br>HR 0.56 (0.39–0.81)<br>RR 0.42 (0.33–0.53) | Meta-analysis |
| Wang, 2022[108] | Multiple countries | SGLT2 inhibitors vs. placebo | Incidence of AF or atrial flatter | 52,951 [20][a] | OR 0.82 (0.73–0.93) | Meta-analysis |
| Abraham, 2021[109] | 11 countries EMPERIAL-Reduced RCT | Empagliflozin vs. placebo | Incidence of AF or atrial flatter | 312 | OR 0.33 (0.01–8.19) | RCT |
| Abraham, 2021[109] | 11 countries EMPERIAL-Preserved RCT | Empagliflozin vs. placebo | Incidence of AF or atrial flatter | 315 | OR 0.66 (0.11–3.99) | RCT |

(Table 3 continues on next page)

| Study | Country | Treatment | Outcomes | Number of patients | Results risk estimate (95% CI) | Level of evidence |
|---|---|---|---|---|---|---|
| (Continued from previous page) | | | | | | |
| McMurray, 2019[300] | 20 countries DAPA-HF RCT | Dapagliflozin vs. placebo | Incidence of AF or atrial flatter | 4744 | OR 0.98 (0.74–1.30) | RCT |
| *Chronic obstructive pulmonary disease* | | | | | | |
| Noubiap, 2023[194] | UK | Pharmacological treatment with achieved FEV1/FVC ratio <0.70 vs ≥ 0.70 | AF incidence | 348,219 | HR 1.23 (1.19–1.28) | Prospective registry (UK biobank) |
| *Chronic kidney disease* | | | | | | |
| Naruse, 2011[216] | Japan | CKD vs. no CKD as modifiers of catheter ablation outcomes | AF recurrence | 221 | HR 2.10 (1.29–3.38) | observational study |
| *Mental health disorders* | | | | | | |
| Cao, 2022[112] | Multiple countries | Antidepressants vs no antidepressants | AF incidence | 2,626,746 [6][a] | RR 1.37 (1.16–1.61) | Systematic review |
| Chou, 2017[221] | Taiwan | Antipsychotics vs no antipsychotics | AF incidence | 68,972 | aOR: 1.17 (1.10–1.26) | Nationwide observational study |

aHR, adjusted hazards ratio; aOR, adjusted odds ratio; AF, atrial fibrillation; BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; FEV, forced expiratory volume; FVC, forced vital capacity; HF, heart failure; HR, hazards ratio; MET, Metabolic equivalent of task; OR, odds ratio; OSA, obstructive sleep apnoea; RCT, randomised controlled trial; SGLT2, Sodium-glucose co-transporter-2. [a]Number of studies in a meta-analysis. No studies assessed the effect of approved treatments for dementia on AF or its outcomes, including donepezil, rivastigmine, galantamine and memantine.

***Table 3:*** **Effect of treatment of modifiable risk factors on incidence of atrial fibrillation.**

## Lipids

Although the association between hypercholesterolaemia and development of atherosclerosis and coronary artery disease (CAD) is well-established,[138] and the presence of CAD increases the risk of AF, the relationship between lipids and incident AF remains unclear. A systematic review,[130] examining the relationship between total cholesterol and incident AF found no significant association. However, several studies reported a reduction in risk of incident AF with elevated total cholesterol (relative risk 0.76–0.94).[25,130,139] Multiple prospective and retrospective cohort studies have shown that high levels of low-density lipoprotein cholesterol (LDL-C), and total cholesterol are associated with lower risk of AF, the so-called 'cholesterol paradox'.[25,140] A recent retrospective analysis of >65,000 people aged 45–60 years free of cardiovascular disease from the Swedish national registries, found a lower risk of incident AF associated with higher levels of LDL-C and total cholesterol (HR 0.64, 95% CI 0.45–0.92; and HR 0.61, 95% CI 0.41–0.99) within the first 5 years of follow-up.[26] In contrast, a higher risk of AF was associated with lower levels of HDL-C, and higher triglycerides.[26]




***Fig. 2:*** Mechanisms linking obesity and risk of atrial fibrillation.

The effect of lipoproteins on haemostasis increases the risk of thromboembolism but the evidence in patients with AF has not yet been well-elucidated, with several studies reporting increased risk of ischaemic stroke with high LDL-C levels[140] with less robust findings for the stroke risk associated with lipoprotein (a), A1 and B1.[140] Lipid management in patients with AF reduces overall cardiovascular risk and its associated complications, and is one of the cardiovascular risk factors in the 'C' component of the ABC pathway.[135]

### Diabetes mellitus

Diabetes mellitus is a recognised risk factor for incident AF.[130] The Framingham Heart Study identified diabetes mellitus as a risk factor for AF and it has been included as component in multiple stroke risk scores.[141] A recent meta-analysis confirmed an 1.28-fold increased relative risk of incident AF associated with diabetes mellitus.[27] In addition, those with pre-diabetes (defined as HbA1c level 5.7%–6.4%) were at 1.2-fold greater relative risk of AF in a meta-analysis of observational studies.[27]

There is some evidence that duration of diabetes and quality of glycaemic control impacts the risk of developing AF. In a population-based case–control study, among patients treated for diabetes, there was a 3% greater risk of incident AF for every extra year of diabetes duration (adjusted odds ratio per year 1.03) and with worsening glycaemic control with adjusted odds approximately 1.5 for HbA1c ranging 7–9, and adjusted odds of about 2 for HbA1c over 9.[95] In a Swedish population-based study, risk of incident AF was only increased in those with 20-years of insulin treatment, or where concomitant cardiovascular disease was present.[96] In other studies,[97] after adjustment for other risk factors/confounders, the risk of incident AF associated with diabetes was not significant. In a healthy Asian population-based study without comorbidities, prehypertension and IFG were important risk factors of AF.[28] There are several common underlying pathophysiological mechanisms underpinning diabetes mellitus and AF, atrial structural remodelling (atrial fibrosis and dilatation), plus electromechanical, and autonomic remodelling, and oxidative stress, inflammation, and glycaemic fluctuations.[142]

Diabetes mellitus is prevalent in 20–25% of people with AF[143] and optimising the management of diabetes is also a key element in the 'C' part of the ABC pathway.[135] Treatment should focus on glycaemic control and management of other risk factors associated with diabetes (obesity, physical inactivity, poor diet, and alcohol consumption). Good glycaemic control reduces the risk of AF by preventing/slowing atrial remodelling, although the evidence is limited and varies by pharmacological agent, with metformin[144] and thiazolidinediones[99] demonstrating a lower risk of incident AF (Table 3). There is no evidence of a reduction in incident AF associated with sulfonylureas or insulin.[142] Further studies are required on the newer glycaemic agents, DDP-4 inhibitors, GLP-1 receptor agonists, and SLGT2 inhibitors which have demonstrated significant reductions in cardiovascular events and death but not on AF incidence to date.[145]

In those with AF, good glycaemic control may reduce AF burden although supporting evidence is limited. A meta-analysis showed greater risk of AF recurrence among patients with higher HbA1c levels following catheter ablation.[64] Diabetes mellitus also increases the risk of thromboembolism in AF and sub-group analyses from the NOAC trials demonstrate a reduction in stroke and systemic embolism, intracranial haemorrhage and cardiovascular death with NOAC compared to warfarin among patients with diabetes.[146]

### Coronary artery disease

The risk of incident AF rises by 60–77% post-myocardial infarction (MI), and AF itself may increase the risk of acute coronary events.[147,148] New-onset AF typically occurs during the first 4 days after acute MI, and is associated with more than doubling of the risk of death, congestive HF, and stroke.[149] Patients with AF and acute coronary syndromes are less likely to receive appropriate antithrombotic therapy and more likely to experience adverse outcomes than patients without AF.[1] Overall, 10–15% of AF patients undergo percutaneous coronary interventions (PCI) for CAD and combined antithrombotic treatment-related benefits and bleeding need to be carefully balanced.[150] Dual antithrombotic therapy including oral anticoagulation (preferably NOAC) and a $P_2Y_{12}$ inhibitor (preferably clopidogrel) is associated with less major bleeding and intracranial haemorrhage than triple therapy. Dual therapy is recommended for the first 12 months after PCI for acute coronary syndromes, or 6 months after PCI for stable CAD.[151] Thereafter, oral anticoagulant monotherapy is continued, similar to patients with stable CAD.[152]

### Heart failure

AF and HF share common risk factors and frequently coexist.[153] About half of patients with HF develop AF, but AF prevalence varies depending on clinical settings (acute versus chronic), left ventricular function, functional class, and HF therapies.[154] AF may exacerbate HF through decreased cardiac output secondary to loss of atrial systole, increased myocardial oxygen consumption and diminished coronary perfusion during rapid ventricular responses, neurohormonal activation and tachycardia-induced cardiomyopathy.[155]

AF increases mortality and thromboembolism in HF.[156] Higher stroke risks are observed in the HF with preserved ejection fraction (HFpEF) than other types of HF.[66] Unless contraindicated, long-term oral anticoagulation is recommended in all patients with HF with AF. NOAC is preferred for the prevention of thromboembolic events in patients with AF.[157] The

efficacy and safety of NOACs is comparable in AF irrespective of HF.[158]

All patients with HF and AF should receive guideline-adherent HF therapy.[159] The optimal heart rate target in AF with HF remains unclear, although a heart rate under 100–110 bpm (lenient rate control) is usually recommended.[159] Higher heart rates are associated with worse outcomes in observational studies.[160,161] The benefit of beta-blocker therapy in reducing mortality in AF patients with HF with reduced ejection fraction (HFrEF) has been questioned by some meta-analyses.[162]

Recent controlled trials and observational analyses demonstrated that early rhythm control therapy is beneficial for AF patients.[155,163–167] Combined with the effectiveness of early rhythm control,[163] these findings suggest a wider use of rhythm control therapy to improve symptoms and quality of life, and provide an additional avenue to prevent outcomes such as stroke and cardiovascular death.[104,163,168] Benefit of early rhythm control was demonstrated in asymptomatic patients,[168] those with heart failure,[104] and high stroke risk.[169] In real-world data, the benefit of early rhythm control was also observed in those with low stroke risk.[170]

In patients with HF and reduced LVEF, two RCTs have shown a reduction in all-cause mortality and hospitalisations with AF catheter ablation.[102,171] The generalizability of the trial has recently been evaluated in a large HF patient population.[105,172] The smaller AMICA (Atrial Fibrillation Management in Congestive Heart Failure With Ablation) RCT, which included patients with more advanced HFrEF, did not show benefits gained by AF catheter ablation at 1-year follow-up,[173] whereas a recent CABANA subgroup analysis supported the benefits of AF catheter ablation in patients with HFrEF.[165] Overall, AF catheter ablation in patients with HFrEF results in higher rates of preserved sinus rhythm and greater improvement in LVEF, exercise performance, and QoL compared with AAD and rate control.[102,171,174–181] A recent single-centre, open-label trial was terminated early given the clear benefits of catheter ablation for symptomatic AF compared to medical therapy in end-stage HF, but improving the composite primary outcome of death from any cause, implantation of a left ventricular assist device or urgent heart transplantation (HR 024, 95% CI 0.11–0.52) and all-cause mortality (HR 0.29, 95% CI 0.12–0.72).[182] Accordingly, AF ablation in patient with HFrEF patients is a class I indication regardless of their symptom status according to the current ESC AF guidelines.[1]

## Cardiomyopathies

AF is common in patients with inherited cardiomyopathies, and maybe the presenting feature.[183] Inherited cardiomyopathies, due to mutations in genes encoding specific structural proteins, are associated with atrial remodelling, histological changes, and modifications in atrial action predisposing to AF.[184] AF may occur as a consequence of disease-specific defects and/or non-specific cardiac chamber changes secondary to the primary illness.[185] AF occurs in 20–30% of patients with hypertrophic cardiomyopathy (HCM) with an annual incidence of 2%.[186,187] AF in HCM is associated with a high risk of strokes, systemic embolism and death.[186–190] Oral anticoagulation is recommended the HCM with AF (considered part of 'C' criterion of $CHA_2DS_2$-VASc score).[191] AF is also common in arrhythmogenic right ventricular dysplasia/cardiomyopathy (11–30%), familial dilated cardiomyopathy (33%), and left ventricular non-compaction cardiomyopathies (1–29%), and associated with worsened prognosis.[185] The risk of stroke is not well-defined in cardiomyopathies except HCM, but there is stronger consensus for oral anticoagulation in left ventricular non-compaction cardiomyopathies with AF/atrial flutter.[65] Maintenance of sinus rhythm has been achieved in up to two-thirds of HCM patients, although repeat procedures or continuation of antiarrhythmic medications are often necessary.[185] The role of ablation procedures in other cardiomyopathies is unclear.

## Respiratory disease

Chronic obstructive pulmonary disease (COPD) is present in up to 23% of AF patients[67] and COPD is associated with a 2-fold increase in AF risk.[192,193] A recent study reported that among 46 studies, the pooled prevalence of COPD was 13% in AF patients. COPD was associated with higher prevalence of comorbidities, higher $CHA_2DS_2$-VASc score and lower beta-blocker prescription. COPD was also associated with higher risk of all-cause death (OR 2.22, 95% CI 1.93–2.55), CV death (OR 1.84, 95% CI 1.39–2.43), and major bleeding (OR 1.45, 95% CI 1.17–1.80); no significant differences in outcomes were observed according to beta-blocker use in AF patients with COPD.[110] Reduced ventilatory function is associated with increased risk of AF independently from age, sex, smoking, and other known AF risk factors.[194] COPD and AF share common risk factors, but COPD might also directly contribute to the onset of AF through right ventricular strain-triggered changes in cardiac geometry and haemodynamics.[193] Both corticosteroids and theophylline used in COPD may increase the risk of AF.[193]

COPD should be suspected and spirometry considered in AF patient with chronic dyspnoea or reduced exercise tolerance, especially as it may co-exist with HF. Acute exacerbation of COPD transiently increases AF risk due to hypoxia-mediated mechanisms, inflammation, increased use of beta-2 agonists, and autonomic changes. COPD in patients with AF is associated with the reduced success of rhythm control strategies using cardioversion or catheter ablation.[195–197] It remains unclear whether treatment of COPD improves AF outcomes.[193] Whilst both the inhaled beta2-agonists and

anticholinergics have been associated with tachyarrhythmias,[198] the risk for cardiac arrhythmias in patients treated by anticholinergics is much lower. Inhaled corticosteroids do not seem to increase AF risk. Studies showed a reduction in mortality and a reduction in exacerbation rate in AF patients with COPD treated by selective beta-1 blockers.[199,200]

### Air pollution

One in five CVD deaths are attributable to air pollution and the effect varies according to age, sex, socioeconomic status, comorbidities, and geographical location.[201,202] Older people, those with concomitant cardiovascular disease, higher BMI, and people from LMICs and Asia (due to the higher levels of air pollution) are at greater risk of AF.[203] Four meta-analyses have demonstrated that increased short-term exposure to air pollution is associated with higher risk of AF but the data regarding long-term exposure was inconsistent.[204–207]

### Renal disease

AF and chronic kidney disease (CKD) also share common risk factors, such as hypertension.[208] They often coexist: 20% of patients with CKD have AF, and 50% of patients with AF have some degree of renal impairment.[209] The risks and benefits of oral anticoagulation in AF may be altered by renal dysfunction.[210] In mild-to-moderate CKD (CrCl 30–49 mL/min), NOACs can be safely used.[211–213] In patients with CrCl 15–29 mL/min, robust RCT-derived data on NOAC use are lacking, even more so for end-stage kidney disease. Observational data questions the benefit of oral anticoagulation in end-stage kidney disease but suggests possible lower bleeding risk of NOACs vs. warfarin.[214,215]

Reduced renal function predisposes to adverse drug effects.[209] Patients with AF and CKD have more periprocedural complications with PCI or catheter ablation,[209] yet, catheter ablation has lower rates of symptomatic AF recurrence compared with drug treatment.[111,165] In patients under haemodialysis, catheter ablation is increasingly performed for rhythm control since the use of antiarrhythmic agents is restricted.[216]

### Mental health disorders

In addition to somatic risk factors, stress, psychological factors, and the state of an individual's mental health may influence the occurrence, symptoms, treatments, and outcomes of AF.[217] The presence of mental health disorders increases the risk of AF perhaps through predisposition to risk factors for AF (e.g., alcohol, illicit substance misuse), inadequate management of risk factors (poor adherence to antihypertensive drugs, lifestyle modifications), or side effects of medications (antipsychotic drugs, lithium).[35,218] The psychological morbidity associated with AF requires close attention given the impact on AF course and quality of life.[40]

Stress is associated with a higher risk of hypertension, and MI, contributed to by adrenergic and endocrine stimulation (especially acute stress) and unhealthy lifestyle behaviours (chronic stress). The Danish National Health Survey showed a higher AF incidence in people with greater perceived stress, but this was non-significant after adjustment for comorbidities, socioeconomic and lifestyle factors.[41] The Swedish Longitudinal Occupational Survey of Health (SLOSH) showed that job strain was independently associated with an almost 50% increase in AF risk, consistent with a recent meta-analysis.[219] However, such analyses do not allow mechanistic insights into the associations. For example, a stressful job may impair adherence to antihypertensive treatments. In contrast, relaxation techniques, such as yoga, may help to mitigate the risk.[38]

Anxiety disorders generally do not increase AF risk,[220] although anxiety is highly prevalent in people with AF. Analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) data found no significant association for anger, anxiety, or chronic stress with the development of AF.[217] However, depression has been consistently related to higher AF incidence. MESA data showed that the presence of depression and the use of antidepressants was associated with a 34% and 36% higher risk of AF, respectively.[217] Also, people with depression tend to have more AF symptoms, which improve with better depression control.[34] Most studies show a higher risk of AF in people with schizophrenia, partially attributed to antipsychotic medications.[36] Antipsychotic drug use poses a dose-dependent AF risk, especially for antipsychotics with higher binding affinity to muscarinic M2 receptors.[221]

In the Danish health registries, only 33.7% of people with schizophrenia received oral anticoagulation within the first year after AF diagnosis, compared with 54.4% of patients without schizophrenia.[222] Bipolar disorder and schizophrenia were associated with a lower frequency of initiation of oral anticoagulation within 90 days after incident AF and lower oral anticoagulant use in patients with prevalent AF.[223] In the Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) registry, a lower proportion of patients with any mental health disorder were initiated on oral anticoagulation (64.9% vs 73.3% with a similar pattern for all considered mental disorders).[78] Non-persistence to NOACs was also reported in people with mental health disorders (HR 1.32 for depression, HR 1.44 for bipolar disorder, and HR 1.30 for schizophrenia). When receiving warfarin, people with bipolar disorder experienced poorer anticoagulation control (time in INR therapeutic range).[224] However, patients with anxiety without other mental health disorders were not at increased risk of non-persistence with oral anticoagulation.[225] These high-quality observational studies are consistent with the results of a systematic review showing that people with

AF and mental health disorders were less likely to receive oral anticoagulation.[79]

It remains unclear if severe mental health disorders increase the risk of AF-related stroke. In the Danish nationwide registry with over 5-years follow up of patients with AF, those diagnosed with schizophrenia, depression or bipolar disorder were not at higher risk of stroke or major bleeding.[226] A systematic review did not find an association between serious mental health illnesses and stroke or major bleeding after adjustment for risk factors for stroke and bleeding.[224] It is likely any excess of AF-related strokes and bleeding in people with mental health disorders is due to poorly controlled risk factors. Although treatment adherence may be challenging for people with mental health disorders, limited data exist on how this influences rhythm and rate control strategies in AF. People with mental health disorders tend to be underrepresented in clinical trials, making the results less generalisable to this population.

### Cognitive impairment

Cognitive impairment does not have established links with the risk of developing AF. There are cautions about prescribing cholinesterase inhibitors used to treat Alzheimer's disease, although these have not been associated with increased risk of AF.[227] In contrast, people with AF are at higher risk of cognitive decline and dementia, including vascular dementia and, to a lesser degree, Alzheimer's disease.[228,229] The risk relates to survivors of AF-related stroke and those without stroke history.[228] AF may increase the dementia risk in those younger than 65.[230] However, the strength of such evidence is inconsistent, and some data only showed a significant and steep increase in dementia risk after the age of 65.[70] Of note, dementia reciprocally puts people with AF at higher risk of cardiovascular and all-cause death.[231]

Proving the causative relationship between AF and dementia is challenging due to the shared risk factors, such as advanced age, hypertension, diabetes, and dyslipidemia. However, the association between AF and cognitive impairment remains after adjusting for these risk factors.[232,233] Repeated ischaemic brain injuries led to stepwise cognitive decline, and stroke survivors had a 2.4-fold risk of dementia in a meta-analysis of observational studies.[229] Silent cerebral infarcts also increased risk of cognitive decline.[234] AF also contributes to cognitive impairment through the chronic decrease in cerebral perfusion due to reduction of the stroke volume (loss of atrial systole), variability of stroke volume (irregular rhythm), atrial-ventricular desynchrony and cerebral vascular dysfuncion.[235,236] Nearly all participants of the SWISS-AF study had brain matter lesions, and about 20% had small infarcts, large infarcts, or microbleeds.[237]

A 27–50%-reduction in dementia rates in people with sinus rhythm restored by catheter ablation supports the mechanistic link between AF and dementia.[238–240] Catheter ablation reduced risk of both vascular dementia and Alzheimer's disease.[238] The prospective European Strat-AF study demonstrated that the risk of cognitive impairment in AF paralleled the risk of stroke quantified using the $CHA_2DS_2$-VASc score.[241] Accordingly, population-level data from Sweden indicated a 56% reduction in dementia risk if people received anticoagulation, especially if the treatment was within the first year of AF diagnosis.[242] Oral anticoagulation was associated with a 60% reduction in dementia risk in AF.[243–246] Adequate OAC is essential in mitigating the risk of AF-related cognitive impairment. Population-level observational studies showed lower incidence of dementia in people managed by rhythm control vs rate control strategy (sub-distribution HR 0.86, 95% CI 0.80–0.93) and in patients treated by ablation vs medical therapy (HR 0.73, 95% CI 0.58–0.93).[238,247] Initial promising data indicate benefits of SGLT2 inhibitors for dementia reduction in AF, but further evidence is needed.[248] Lifestyle improvement reduces the risk of dementia in AF, especially regular exercise (adjusted HR 0.66; 95% CI 0.61–0.72) and smoking cessation (HR 0.83, 95% CI 0.72–0.95).[89,249] While AF increases the risk of dementia, integrated care mitigates the risk. Adherence to the ABC pathway reduced the risk of dementia by 20%.[250]

### Frailty

Frailty is a clinical state characterised by a decrease in homeostatic reserves, vulnerability to endogenous and exogenous stressors, and increased risk of adverse health-related outcomes.[72] People with frailty often have multimorbidity and polypharmacy and need special consideration regarding optimal AF management. Studies vary on frailty assessment methods and thresholds that must be considered when interpreting study results. The prevalence of frailty in patients with AF ranged between 5.9% and 89.5%, influenced by assessment method, age, history of stroke, and geographical location.[251] The overall prevalence of frailty in AF patients in the community is estimated at 17%, which is higher than previous estimates (12% prevalence) in general community cohorts, irrespective of frailty tools used for assessment.[252] Analyses of the ESC-EHRA EORP-AF General Long-Term Registry of 10,177 AF patients predominantly recruited from secondary care identified 21.3% as frail.[75] A pooled analysis of 33 studies (1,187,651 patients) showed a frailty prevalence of 39.7% (95 %CI 29.9 %–50.5%).[253] The variability likely reflects different approaches studies used to define frailty and the frailty spectrum of patients.

In people with AF, frailty was associated with increased stroke incidence, all-cause mortality, and major bleeding.[251] Frailty is a stronger predictor of mortality in patients with AF than in the general population.[77] Frail patients were less likely to receive oral

anticoagulation (OR 0.70, 95% CI 0.55–0.89) and were at higher risk of death (HR 3.54, 95% CI 2.56–4.89), MACE (HR 3.41, 95% CI 2.44–4.77) and major bleeding (HR 2.87, 95% CI 1.55–5.29).[75] The frailty assessment method influences the effect sizes, with the pooled relative risk for mortality at 4.93 for the frailty index and 1.63 for the frailty scale.[251] The impact of severity of comorbidities is higher in older populations, and frailty is thus more predictive of mortality in relatively younger populations.[251] In an adjusted analysis of the ORBIT-AF registry, frailty was independently associated with all-cause death but was no longer associated with thromboembolic or bleeding risk.[71]

Data on the impact of OAC prescribing on people with frailty are inconsistent.[253] OAC prescription is influenced by age, baseline thromboembolic risk, and study setting.[254] Analysis of the Systematic Assessment of Geriatric Elements in Atrial Fibrillation (SAGE-AF) database found no relationship between frailty status and OAC prescribing.[73] In the nationwide English primary care cohort, a progressively higher burden of frailty was associated with a higher prescription of OAC.[255] An Irish community-based study showed higher rates of OAC prescribing in people with frailty.[256] In contrast, among nursing residents, only 25% of eligible patients were prescribed OAC.[74] OAC prescribing in people with frailty is influenced by competing indications and risks in this vulnerable population.

There is a limited evidence base to guide OAC prescribing in people with frailty to account for individual risks of bleeding complications accurately. However, in an ENGAGE AF-TIMI 48 trial analysis, participants with mild-to-moderate frailty showed a lower risk for all the composite clinical endpoints and death risk for edoxaban vs warfarin.[257] Similarly, in favourable outcome profile for NOACs vs warfarin was reported in the ARISTOPHANES registry population of frail patients,[258] and the nationwide AF cohort of Korea.[259] Also, rhythm-control vs rate-controlled strategy did not significantly reduce a combined cardiovascular outcome in AF patients with moderate-severe frailty.[260] A holistic approach is therefore needed, as promoted by the ABC pathway.[135] Adherence to the ABC pathway reduced the risk of all-cause death by 26%.[261] Chronological age per se should not be used as a metric of frailty. Frailty assessment should be considered for optimal pharmacological management of multimorbidity but should not restrict the use of oral anticoagulation.

## Multimorbidity and polypharmacy

People with AF often experience multimorbidity (70–80%) and polypharmacy (40–95%).[262] Ageing and accumulation of co-existing conditions increase risk of AF and its complications, such as stroke.[263] Multimorbidity is associated with high mortality, reduced functional status, and increased healthcare expenditure in observational studies and in the multimorbidity subgroup of the mAFA-II RCT.[116,262,264]

Polypharmacy, the intake of ≥5 drugs, is a well-established prognosticator of poor health outcomes due to drug–drug interactions overlaying comorbidities.[265–267] Treatment with warfarin requires particularly careful consideration in view of multiple food- and drug–drug interactions.[268] However, polypharmacy negatively influences prognosis in AF irrespective of use of oral anticoagulation.[269] Polypharmacy was associated with higher stroke or systemic embolism in analysis of Belgian nationwide data (adjusted HR 1.08, 95% CI 1.02–1.15), mortality (adjusted HR 1.45, 95% 1.40–1.50), and major bleeding risks (adjusted HR 1.29, 95% CI 1.23–1.35).[270] Despite fewer interactions, NOACs still increase potential drug interactions in polypharmacy. In ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 trials, patients with polypharmacy had similar relative benefits from NOACs, despite higher absolute event rates (particularly bleeding and deaths) compared to people without polypharmacy.[266,267,271] In a meta-analysis of RCTs and observational studies (12 studies, 767,544 patients) NOACs compared with VKAs reduced risk of stroke or systemic embolism in AF patients with moderate polypharmacy (HR 0.77, 95% CI 0.69–0.86) and severe polypharmacy (HR 0.76, 95% CI 0.69–0.82), without affecting the risk of bleeding.[272] In contrast, warfarin use posed excess risk of adverse events in polypharmacy. These data indicate that polypharmacy itself should not be a barrier for NOAC use but requires careful and holistic approach for prescribing (ABC pathway).[273,274]

## Patient factors

### Gender

The impact of gender and sex in AF-related risk is complex, with significant gaps in knowledge. Available studies focus on sex and lack data on the role of gender identity. Despite men traditionally reported to have a 30–70% higher incidence and prevalence of AF than women, due to the greater longevity in women, the lifelong risk of AF is similar.[275,276] Women with AF tend have a higher risk of mortality and stroke.[277,278] The reasons why women are at higher risk of complications may be related to biological factors (e.g., sex hormones) but are also related to socio-economic and psychological factors and reduced healthcare access.

Women are usually older at the time of AF diagnosis and have higher $CHA_2DS_2$-VASc scores.[279] However, higher $CHA_2DS_2$-VASc scores are partly due to the female gender contributing to the score (1 point); sex is increasingly considered as a risk modifier rather than a risk factor per se.[279] UK data show that while women were less likely to receive oral anticoagulation and have a higher risk of stroke, the stroke risk was similar in anticoagulated men and women.[280] Several European

registries have shown that women with AF are more symptomatic than men, with atypical symptoms such as dyspnea, chest pain, and fatigue, which may mask initial presentation.[281] Sex-related psychological factors, including the stress response, may also contribute to AF risk. Toxic psychosocial stress was linked to AF risk in women (but not men) in the Malmö Diet Cancer Study in Europe and the Women's Health Study.[282,283] The PaTH AF cohort study showed a correlation between severe AF symptoms and symptoms of anxiety and depression in women. However, it remains unclear whether this modifies healthcare-seeking behaviour and outcomes.[284]

### Ethnic minority groups, migrants

The risk of AF varies between ethnic groups (Fig. 3). Although few European countries collect data on ethnicity, the UK CPRD data show a higher standardised AF incidence (per 1000) in White people (8.1, 95% CI 8.1–8.2) than in Asians (5.4, 95% CI 4.6–6.3) and Black origin individuals (4.6, 95% CI 4.0–5.3).[32] The South Asian diaspora is one of the largest ethnic minority groups in Europe and worldwide. A retrospective UK cohort population-based study using The Health Improvement Network (THIN) data showed that people of South Asian origin, compared to White ethnicity, were at an increased risk of type 2 diabetes, hypertension, coronary artery disease and HF but had a 2-fold lower risk of AF.[33] Similarly, among UK stroke survivors, AF was present in 13% of South Asians vs 22.7% of white British participants. The ethnicity-related risk of South Asians having AF was lower despite the higher rates of traditional risk factors (odds ratio for AF 0.40 after adjustment for risk factors). Both ethnic groups have similar rates of oral anticoagulation prescribing on admission and discharge.[285] People of South Asian ethnicity eligible for the NHS Health Check, attend it more often than any other ethnic group, especially South Asian women.[286] This is likely to help mitigate the higher overall cardiovascular risk in the South Asian population. Similar to South Asian ethnicity, people of African origin have a lower lifetime risk of AF compared to White ethnicity.[287] The Multi-Ethnic Study of Atherosclerosis (MESA) in the USA also reported the highest risk of AF in White subjects, with lower rates in Hispanic individuals, followed by those of Black and Chinese ethnicity.[288] White people of Latin background have a lower adjusted risk of AF than white people of other origin (HR 0.76, 95% CI 0.75–0.77).[289]




*Fig. 3:* Ethnicity and risk of atrial fibrillation.

Despite the lower risk of AF, people of non-White ethnicity are at higher risk of complications when AF occurs. In the ARIC study, Black people had a 1.5–2.0-fold higher rate difference for stroke, heart failure and CHD vs. White people.[290] A systematic review suggests a possibly lower overall likelihood of receiving anticoagulant prescriptions among Black patients than among White patients.[79] However, high-quality data in European regions are lacking. Overall, belonging to ethnic minority groups is unlikely to contribute to AF-related risk significantly and is not part of established tools for stroke risk prediction.

Globally, the highest rates of AF were estimated in North America and the lowest in the Asia–Pacific and Sub-Saharan regions.[275,291] There are regional differences in the effects of individual risk factors with hypertension having a higher impact in Southern Sub-Saharan Africa and Central Asia and excessive weight in Eastern and Central Europe.[292] The gradual decline in AF incidence and prevalence in countries with the high socio-demographic index contrasts with the growing AF rates in countries with middle and low socio-demographic indexes.[292] New data also showed a 2-fold rise in AF prevalence in China.[293]

### Socio-economic factors/deprivation, care access

Data on the association of socioeconomic status (SES) and AF risk are inconsistent, with only some studies demonstrating lower incidence of AF in higher SES groups.[294] This likely reflects SES definitions and healthcare service access and population risk factor profile.[295] In those with AF, SES was associated with poorer outcomes, including increased risk of mortality and morbidity in a systematic review of 39 studies.[295] A Swedish primary care cohort of 12,283 patients with AF aged ≥45 years found 1.49-fold higher mortality among men from low vs. middle SES neighbourhoods.[296] Further, in a Danish nationwide registry cohort, lower SES was associated with a higher risk of HF or stroke, less likelihood of cardioversion or catheter ablation, and a higher mortality.[297]

There are significant differences in AF treatment by SES and access (geographical) to care. A Norwegian

### Search strategy and selection criteria

We searched PubMed for original articles and reviews published in English up to 14th February 2023, using the search terms: "atrial fibrillation", "risk factors", "patient factors" or individual risk factors, listed as section headings in the review. We also searched the reference lists of articles identified by this search strategy and selected those we judged to be relevant, including publications and other data sources that we considered important contributions to the topic. We prioritised publications reporting findings from the European regions and complemented them with global data where appropriate.

national population-based cohort found that those from higher SES groups (higher level of education and high income) and who lived closer to the referring hospital were more likely to receive catheter ablation.[298] A Finnish cohort study found that patients who were better educated or had higher incomes were more adherent initially but there was no difference in long-term adherence by SES.[299] The SES differences in outcomes may be associated with access to care particularly in countries where healthcare is not free at the point of need, with poorer health literacy and ability for self-advocacy for appropriate treatments, and ability to adhere to medication and lifestyle modifications to self-manage AF. There is a need for greater allocation of resources in primary care in more deprived areas.

Tackling the social determinants of health (SDoH), early childhood development, economic circumstance, neighbourhood and built environment, social and community context, and health and healthcare (health literacy), could contribute to decreased CVD burden. A recent umbrella review of SDoH demonstrated a greater risk of CVD morbidity and mortality for those with lower or worse SDoH in all domains except health; there were no reviews on health literacy and CVD risk.[12] There is less data for the impact of SDoH on AF and existing data is inconsistent. This umbrella review suggests that addressing childhood development (ensuring education access and quality and preventing adverse childhood events) and the economic environment (stable employment/occupation, food and housing security, and income) within a multifactorial risk factor-based approach, could substantially impact CVD risk and burden.

## Summary and future directions

The multitude of factors contributing to AF pathogenesis calls for a holistic, comprehensive approach to their identification and management, essential for AF prevention and reducing the burden of its complications. Risk factors often co-exist, influencing and amplifying their overall effect. Also, the magnitude of the impact of individual risk factors varies by patient factors, including gender and ethnicity, access to healthcare resources, and resources for an optimal lifestyle. It is currently unclear how to account for all these factors for individual risk prediction beyond the existing scoring systems. This requires new predictive models based on advanced statistical methods and machine learning techniques to account for longer-term trajectories in risk factors. Risk prediction would need to be supplemented by developing tailored therapeutic approaches. Successful mitigation of AF-related health requires an individualised approach considering all somatic, psychological, demographic, and social factors. This can be challenging, particularly with the increasing multimorbidity, polypharmacy and changing population demographics, across the European region. At present, attention should be paid to meticulous following of the ABC pathway approach. It is crucial to engage the patient as partners in the discussions of the lifestyle modifications and treatment options, with access to education, clinical feedback, and access for advice. Particular support is needed for people who may have cognitive impairment, physical disabilities, disabilities, or belonging to hard-to-reach groups. A multidisciplinary approach is vital for future research and practice to achieve optimal management of risk factors for AF.[300]

#### Contributors

ES: conceptualisation, writing—original draft, writing—review & editing, project administration. EKC: conceptualisation, writing—original draft, writing—review & editing. DAL: conceptualisation, writing—original draft, writing—review & editing. BJ: conceptualisation, writing—original draft, writing—review & editing. GYHL: conceptualisation, writing—review & editing.

#### Declaration of interests

ES: none; EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd., Medtronic, Samjinpharm, Seers Technology, and Skylabs; DAL: DAL has received investigator-initiated educational grants from Bristol Myers Squibb (BMS) and Pfizer; been a speaker for Boehringer Ingelheim, BMS/Pfizer and Bayer, and consulted for Boehringer Ingelheim and BMS/Pfizer; all outside the submitted work. DAL is also a co-applicant on EU Commission funded projects on atrial fibrillation; BJ: none; GYL: reports consultancy and speaker fees from BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo outside the submitted work. No fees received personally.

#### Acknowledgements

None.

#### References

1 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373–498.
2 Faselis C, Kokkinos P, Tsimploulis A, et al. Exercise capacity and atrial fibrillation risk in veterans: a cohort study. *Mayo Clin Proc*. 2016;91(5):558–566.

3 Kato M, Kubo A, Nihei F, Ogano M, Takagi H. Effects of exercise training on exercise capacity, cardiac function, BMI, and quality of life in patients with atrial fibrillation: a meta-analysis of randomized-controlled trials. *Int J Rehabil Res*. 2017;40(3):193–201.
4 Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. *Circulation*. 2008;118(8):800–807.
5 Garnvik LE, Malmo V, Janszky I, Wisloff U, Loennechen JP, Nes BM. Physical activity modifies the risk of atrial fibrillation in obese individuals: the HUNT3 study. *Eur J Prev Cardiol*. 2018;25(15):1646–1652.
6 Bonnesen MP, Frodi DM, Haugan KJ, et al. Day-to-day measurement of physical activity and risk of atrial fibrillation. *Eur Heart J*. 2021;42(38):3979–3988.
7 Andersen K, Farahmand B, Ahlbom A, et al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. *Eur Heart J*. 2013;34(47):3624–3631.
8 Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. *Eur Heart J*. 2008;29(1):71–78.
9 Malmo V, Nes BM, Amundsen BH, et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. *Circulation*. 2016;133(5):466–473.
10 Reed JL, Terada T, Vidal-Almela S, et al. Effect of high-intensity interval training in patients with atrial fibrillation: a randomized clinical trial. *JAMA Netw Open*. 2022;5(10):e2239380.
11 Svedberg N, Sundstrom J, James S, Hallmarker U, Hambraeus K, Andersen K. Long-term incidence of atrial fibrillation and stroke among cross-country skiers. *Circulation*. 2019;140(11):910–920.
12 Teshale AB, Htun HL, Owen A, et al. The role of social determinants of health in cardiovascular diseases: an umbrella review. *J Am Heart Assoc*. 2023;12(13):e029765.
13 Jin MN, Yang PS, Song C, et al. Physical activity and risk of atrial fibrillation: a nationwide cohort study in general population. *Sci Rep*. 2019;9(1):13270.
14 Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. *JACC Clin Electrophysiol*. 2015;1(3):139–152.
15 Cadby G, McArdle N, Briffa T, et al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. *Chest*. 2015;148(4):945–952.
16 Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies. *Eur J Prev Cardiol*. 2018;25(13):1437–1451.
17 Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. *J Am Coll Cardiol*. 2014;64(3):281–289.
18 Shen J, Johnson VM, Sullivan LM, et al. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. *Am J Clin Nutr*. 2011;93(2):261–266.
19 Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. *Am J Clin Nutr*. 2010;92(3):509–514.
20 Cheng M, Hu Z, Lu X, Huang J, Gu D. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. *Can J Cardiol*. 2014;30(4):448–454.
21 Bazal P, Gea A, Navarro AM, et al. Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts. *Eur J Prev Cardiol*. 2021;28(6):648–657.
22 Bodar V, Chen J, Gaziano JM, Albert C, Djousse L. Coffee consumption and risk of atrial fibrillation in the physicians' health study. *J Am Heart Assoc*. 2019;8(15):e011346.
23 Rattani A, Claxton JS, Ali MK, Chen LY, Soliman EZ, Alvaro A. Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in the Atherosclerosis Risk in Communities study. *BMC Cardiovasc Disord*. 2019;19(1):262.
24 Lee SR, Park CS, Choi EK, et al. Hypertension burden and the risk of new-onset atrial fibrillation: a nationwide population-based study. *Hypertension*. 2021;77(3):919–928.
25 Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association of lipoprotein measures with incident atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2014;7(4):612–619.
26 Ding M, Wennberg A, Gigante B, Walldius G, Hammar N, Modig K. Lipid levels in midlife and risk of atrial fibrillation over 3 decades-Experience from the Swedish AMORIS cohort: a cohort study. *PLoS Med*. 2022;19(8):e1004044.
27 Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. *J Diabetes Complications*. 2018;32(5):501–511.
28 Lee SS, Ae Kong K, Kim D, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. *Eur Heart J*. 2017;38(34):2599–2607.
29 Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. *Circ J*. 2011;75(12):2767–2774.
30 Grymonprez M, Vakaet V, Kavousi M, et al. Chronic obstructive pulmonary disease and the development of atrial fibrillation. *Int J Cardiol*. 2019;276:118–124.
31 Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. *J Am Heart Assoc*. 2012;1(4):e002097.
32 Martinez C, Katholing A, Wallenhorst C, Granziera S, Cohen AT, Freedman SB. Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. *Heart*. 2015;101(21):1748–1754.
33 Almulhem M, Chandan JS, Gokhale K, et al. Cardio-metabolic outcomes in South Asians compared to White Europeans in the United Kingdom: a matched controlled population-based cohort study. *BMC Cardiovasc Disord*. 2021;21(1):320.
34 von Eisenhart Rothe A, Hutt F, Baumert J, et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis–data from the German Competence Network on Atrial Fibrillation. *Europace*. 2015;17(9):1354–1362.
35 Ahn HJ, Lee SR, Choi EK, et al. Increased risk of incident atrial fibrillation in young adults with mental disorders: a nationwide population-based study. *Heart Rhythm*. 2023;20(3):365–373.
36 Ahn HJ, Lee SR, Choi EK, et al. Increased risk of incident atrial fibrillation in young adults with mental disorders: a nationwide population-based study. *Heart Rhythm*. 2022;20(3):365–373.
37 Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Circ Arrhythm Electrophysiol*. 2011;4(1):26–32.
38 Wahlstrom M, Rydell Karlsson M, Medin J, Frykman V. Effects of yoga in patients with paroxysmal atrial fibrillation - a randomized controlled study. *Eur J Cardiovasc Nurs*. 2017;16(1):57–63.
39 Du H, Yang L, Hu Z, Zhang H. Anxiety is associated with higher recurrence of atrial fibrillation after catheter ablation: a meta-analysis. *Clin Cardiol*. 2022;45(3):243–250.
40 Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. *Chest*. 2007;132(4):1259–1264.
41 Graff S, Prior A, Fenger-Gron M, et al. Does perceived stress increase the risk of atrial fibrillation? A population-based cohort study in Denmark. *Am Heart J*. 2017;188:26–34.
42 Garnvik LE, Malmo V, Janszky I, et al. Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study. *Eur Heart J*. 2020;41(15):1467–1475.
43 Proietti M, Boriani G, Laroche C, et al. Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. *Europace*. 2017;19(4):535–543.
44 Ahn HJ, Lee SR, Choi EK, et al. Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: a nationwide population-based cohort study. *PLoS Med*. 2021;18(6):e1003659.
45 Jin MN, Yang PS, Yu HT, et al. Association of physical activity with primary cardiac arrest risk in the general population: a nationwide cohort study of the dose-response relationship. *Mayo Clin Proc*. 2022;97(4):716–729.
46 Yoon M, Yang PS, Jin MN, et al. Association of physical activity level with risk of dementia in a nationwide cohort in Korea. *JAMA Netw Open*. 2021;4(12):e2138526.
47 Dai Q, Mehawej J, Saczynski JS, et al. Usefulness of self-reported physical activity and clinical outcomes in older patients with atrial fibrillation. *Am J Cardiol*. 2022;181:32–37.

48 Delgado V, Di Biase L, Leung M, et al. Structure and function of the left atrium and left atrial appendage: AF and stroke implications. *J Am Coll Cardiol*. 2017;70(25):3157–3172.
49 Tonnesen J, Pallisgaard J, Ruwald MH, et al. Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study. *Europace*. 2023;25(2):425–432.
50 Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. *Am J Med*. 2013;126(7):640.e9–17.
51 Holmqvist F, Guan N, Zhu Z, et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Am Heart J*. 2015;169(5):647–654.e2.
52 Zhu W, Guo L, Hong K. Relationship between smoking and adverse outcomes in patients with atrial fibrillation: a meta-analysis and systematic review. *Int J Cardiol*. 2016;222:289–294.
53 Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. *BMC Cardiovasc Disord*. 2005;5:20.
54 Qiao Y, Shi R, Hou B, et al. Impact of alcohol consumption on substrate remodeling and ablation outcome of paroxysmal atrial fibrillation. *J Am Heart Assoc*. 2015;4(11):e002349.
55 Takigawa M, Takahashi A, Kuwahara T, et al. Impact of alcohol consumption on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation. *J Am Heart Assoc*. 2016;5(12):e004149.
56 Overvad TF, Rasmussen LH, Skjoth F, et al. Alcohol intake and prognosis of atrial fibrillation. *Heart*. 2013;99(15):1093–1099.
57 Lim C, Kim TH, Yu HT, et al. Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. *Europace*. 2021;23(4):548–556.
58 Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. *Eur Heart J*. 2021;42(46):4759–4768.
59 Vemulapalli S, Hellkamp AS, Jones WS, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial. *Am Heart J*. 2016;178:74–84.
60 Fransson EI, Nordin M, Magnusson Hanson LL, Westerlund H. Job strain and atrial fibrillation - results from the Swedish Longitudinal Occupational Survey of Health and meta-analysis of three studies. *Eur J Prev Cardiol*. 2018;25(11):1142–1149.
61 Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. *J Am Coll Cardiol*. 2018;72(11):1233–1245.
62 Kim TH, Yang PS, Yu HT, et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. *Eur Heart J*. 2019;40(10):809–819.
63 Kim D, Yang PS, Jang E, et al. Blood pressure control and dementia risk in midlife patients with atrial fibrillation. *Hypertension*. 2020;75(5):1296–1304.
64 Anselmino M, Matta M, D'Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. *Europace*. 2015;17(10):1518–1525.
65 Finsterer J, Stollberger C. Primary prophylactic anticoagulation is mandatory if noncompaction is associated with atrial fibrillation or heart failure. *Int J Cardiol*. 2015;184:268–269.
66 Uhm JS, Kim J, Yu HT, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. *ESC Heart Fail*. 2021;8(2):1582–1589.
67 Proietti M, Laroche C, Drozd M, et al. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: a report from the EUROObservational research programme pilot survey on atrial fibrillation (EORP-AF) general registry. *Am Heart J*. 2016;181:83–91.
68 Hirayama A, Goto T, Shimada YJ, Faridi MK, Camargo CA Jr, Hasegawa K. Acute exacerbation of chronic obstructive pulmonary disease and subsequent risk of emergency department visits and hospitalizations for atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2018;11(9):e006322.
69 Ocak G, Khairoun M, Khairoun O, et al. Chronic kidney disease and atrial fibrillation: a dangerous combination. *PLoS One*. 2022;17(4):e0266046.
70 Giannone ME, Filippini T, Whelton PK, et al. Atrial fibrillation and the risk of early-onset dementia: a systematic review and meta-analysis. *J Am Heart Assoc*. 2022;11(14):e025653.
71 Madhavan M, Holmes DN, Piccini JP, et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. *Am Heart J*. 2019;211:77–89.
72 Cesari M, Calvani R, Marzetti E. Frailty in older persons. *Clin Geriatr Med*. 2017;33(3):293–303.
73 Saczynski JS, Sanghai SR, Kiefe CI, et al. Geriatric elements and oral anticoagulant prescribing in older atrial fibrillation patients: sage-af. *J Am Geriatr Soc*. 2020;68(1):147–154.
74 O'Caoimh R, Igras E, Ramesh A, Power B, O'Connor K, Liston R. Assessing the appropriateness of oral anticoagulation for atrial fibrillation in advanced frailty: use of stroke and bleeding risk-prediction models. *J Frailty Aging*. 2017;6(1):46–52.
75 Proietti M, Romiti GF, Vitolo M, et al. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. *Age Ageing*. 2022;51(8):afac192.
76 Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. *Int J Cardiol*. 2013;168(5):4678–4684.
77 Chang SF, Lin PL. Frail phenotype and mortality prediction: a systematic review and meta-analysis of prospective cohort studies. *Int J Nurs Stud*. 2015;52(8):1362–1374.
78 Jaakkola J, Teppo K, Biancari F, et al. The effect of mental health conditions on the use of oral anticoagulation therapy in patients with atrial fibrillation: the FinACAF study. *Eur Heart J Qual Care Clin Outcomes*. 2022;8(3):269–276.
79 Khatib R, Glowacki N, Byrne J, Brady P. Impact of social determinants of health on anticoagulant use among patients with atrial fibrillation: systemic review and meta-analysis. *Medicine (Baltimore)*. 2022;101(35):e29997.
80 Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. *Age Ageing*. 2009;38(2):156–162.
81 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA*. 2013;310(19):2050–2060.
82 Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol*. 2014;64(21):2222–2231.
83 Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (Legacy). *J Am Coll Cardiol*. 2015;65(20):2159–2169.
84 Gessler N, Willems S, Steven D, et al. Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial. *Europace*. 2021;23(10):1548–1558.
85 Azarbal F, Stefanick ML, Salmoirago-Blotcher E, et al. Obesity, physical activity, and their interaction in incident atrial fibrillation in postmenopausal women. *J Am Heart Assoc*. 2014;3(4):e001127.
86 Qureshi WT, Nasir UB, Alqalyoobi S, et al. Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea. *Am J Cardiol*. 2015;116(11):1767–1773.
87 Patel D, Mohanty P, Di Biase L, et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. *Circ Arrhythm Electrophysiol*. 2010;3(5):445–451.
88 Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH. Smoking cessation after diagnosis of new-onset atrial fibrillation and the risk of stroke and death. *J Clin Med*. 2021;10(11):2238.
89 Lee HJ, Lee SR, Choi EK, et al. Risk of dementia after smoking cessation in patients with newly diagnosed atrial fibrillation. *JAMA Netw Open*. 2022;5(6):e2217132.
90 Dixit S, Alonso A, Vittinghoff E, Soliman EZ, Chen LY, Marcus GM. Past alcohol consumption and incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. *PLoS One*. 2017;12(10):e0185228.
91 Hunt TE, Traaen GM, Aakeroy L, et al. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. *Heart Rhythm*. 2022;19(9):1433–1441.
92 Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol abstinence in drinkers with atrial fibrillation. *N Engl J Med*. 2020;382(1):20–28.
93 Pinho-Gomes AC, Azevedo L, Copland E, et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in

patients with atrial fibrillation: an individual participant data meta-analysis. *PLoS Med*. 2021;18(6):e1003599.
94 Takahashi Y, Nitta J, Kobori A, et al. Alcohol consumption reduction and clinical outcomes of catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2021;14(6):e009770.
95 Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med*. 2010;25(8):853–858.
96 Larsson SC, Wallin A, Hakansson N, Stackelberg O, Back M, Wolk A. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. *Int J Cardiol*. 2018;262:66–70.
97 Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. *Heart*. 2012;98(2):133–138.
98 Emdin CA, Callender T, Cao J, Rahimi K. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. *Europace*. 2015;17(5):701–710.
99 Zhang Z, Zhang X, Korantzopoulos P, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. *BMC Cardiovasc Disord*. 2017;17(1):96.
100 Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. *Int J Cardiol*. 2012;156(2):199–202.
101 Hiraya D, Sato A, Hoshi T, et al. Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: importance of ischemia in managing atrial fibrillation. *J Cardiovasc Electrophysiol*. 2019;30(9):1491–1498.
102 Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med*. 2018;378(5):417–427.
103 Kornej J, Hindricks G, Arya A, et al. Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: the Leipzig Heart Center AF Ablation Registry. *Int J Cardiol*. 2015;181:188–192.
104 Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. *Circulation*. 2021;144(11):845–858.
105 Yang PS, Kim D, Sung JH, et al. Reduction of mortality by catheter ablation in real-world atrial fibrillation patients with heart failure. *Sci Rep*. 2021;11(1):4694.
106 Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. *Circulation*. 2021;143(14):1377–1390.
107 Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. *Circ Arrhythm Electrophysiol*. 2019;12(9):e007414.
108 Wang M, Zhang Y, Wang Z, Liu D, Mao S, Liang B. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis. *J Thorac Dis*. 2022;14(5):1620–1637.
109 Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. *Eur Heart J*. 2021;42(6):700–710.
110 Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. *Eur Heart J*. 2021;42(35):3541–3554.
111 Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321(13):1275–1285.
112 Cao Y, Zhou M, Guo H, Zhu W. Associations of antidepressants with atrial fibrillation and ventricular arrhythmias: a systematic review and meta-analysis. *Front Cardiovasc Med*. 2022;9:840452.
113 AbuElkhair A, Boidin M, Buckley BJR, et al. Effects of different exercise types on quality of life for patients with atrial fibrillation: a systematic review and meta-analysis. *J Cardiovasc Med*. 2023;24(2):87–95.
114 Buckley BJRLL, Risom SS, Lane DA, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. *Cochrane Database Syst Rev*. 2017;2(2):CD011197.
115 Semaan S, Dewland TA, Tison GH, et al. Physical activity and atrial fibrillation: data from wearable fitness trackers. *Heart Rhythm*. 2020;17(5 Pt B):842–846.
116 Yao Y, Guo Y, Lip GYH, m Afaiiti. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial. *JAMA Netw Open*. 2021;4(12):e2140071.
117 Middeldorp ME, Pathak RK, Meredith M, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. *Europace*. 2018;20(12):1929–1935.
118 Groh CA, Vittinghoff E, Benjamin EJ, Dupuis J, Marcus GM. Childhood tobacco smoke exposure and risk of atrial fibrillation in adulthood. *J Am Coll Cardiol*. 2019;74(13):1658–1664.
119 Voskoboinik A, Prabhu S, Ling LH, Kalman JM, Kistler PM. Alcohol and atrial fibrillation: a sobering review. *J Am Coll Cardiol*. 2016;68(23):2567–2576.
120 Artin B, Singh M, Richeh C, Jawad E, Arora R, Khosla S. Caffeine-related atrial fibrillation. *Am J Ther*. 2010;17(5):e169–e171.
121 Conlay LA, Conant JA, deBros F, Wurtman R. Caffeine alters plasma adenosine levels. *Nature*. 1997;389(6647):136.
122 Metro D, Cernaro V, Santoro D, et al. Beneficial effects of oral pure caffeine on oxidative stress. *J Clin Transl Endocrinol*. 2017;10:22–27.
123 Casiglia E, Tikhonoff V, Albertini F, et al. Caffeine intake reduces incident atrial fibrillation at a population level. *Eur J Prev Cardiol*. 2018;25(10):1055–1062.
124 Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. *Circulation*. 2004;110(4):364–367.
125 Stevenson IH, Teichtahl H, Cunnington D, Ciavarella S, Gordon I, Kalman JM. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. *Eur Heart J*. 2008;29(13):1662–1669.
126 Goudis CA, Ketikoglou DG. Obstructive sleep and atrial fibrillation: pathophysiological mechanisms and therapeutic implications. *Int J Cardiol*. 2017;230:293–300.
127 Chen W, Cai X, Yan H, Pan Y. Causal effect of obstructive sleep apnea on atrial fibrillation: a mendelian randomization study. *J Am Heart Assoc*. 2021;10(23):e022560.
128 Nalliah CJ, Wong GR, Lee G, et al. Impact of CPAP on the atrial fibrillation substrate in obstructive sleep apnea: the SLEEP-AF study. *JACC Clin Electrophysiol*. 2022;8(7):869–877.
129 Chung F, Abdullah HR, Liao P. STOP-bang questionnaire: a practical approach to screen for obstructive sleep apnea. *Chest*. 2016;149(3):631–638.
130 Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. *Thromb Haemost*. 2017;117(5):837–850.
131 Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. *Epidemiology*. 2003;14(6):666–672.
132 Choi J, Lee SR, Choi EK, et al. Accumulated hypertension burden on atrial fibrillation risk in diabetes mellitus: a nationwide population study. *Cardiovasc Diabetol*. 2023;22(1):12.
133 Lee SR, Choi YJ, Choi EK, et al. Blood pressure variability and incidence of new-onset atrial fibrillation: a nationwide population-based study. *Hypertension*. 2020;75(2):309–315.
134 Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. *Hypertension*. 2017;70(5):854–861.
135 Lip GYH. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol*. 2017;14(11):627–628.
136 Rao MP, Halvorsen S, Wojdyla D, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *J Am Heart Assoc*. 2015;4(12):e002015.
137 Nagarakanti R, Wallentin L, Noack H, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY trial). *Am J Cardiol*. 2015;116(8):1204–1209.
138 Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. AN evaluation of several serum lipids as predictors of coronary heart disease; the framingham study. *Ann Intern Med*. 1964;61:888–899.
139 Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically

diverse population: the CHARGE-AF consortium. *J Am Heart Assoc*. 2013;2(2):e000102.
140 Ding WY, Protty MB, Davies IG, Lip GYH. Relationship between lipoproteins, thrombosis, and atrial fibrillation. *Cardiovasc Res*. 2022;118(3):716–731.
141 Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA*. 1994;271(11):840–844.
142 Wang A, Green JB, Halperin JL, Piccini JP, Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. *J Am Coll Cardiol*. 2019;74(8):1107–1115.
143 Ding WY, Kotalczyk A, Boriani G, et al. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. *Eur J Intern Med*. 2022;103:41–49.
144 Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. *Cardiovasc Diabetol*. 2014;13:123.
145 Fatima K, Suri A, Rija A, et al. The effect of sodium-glucose Co-transporter 2 inhibitors on stroke and atrial fibrillation: a systematic review and meta-analysis. *Curr Probl Cardiol*. 2023;48(4):101582.
146 Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. *Nat Rev Cardiol*. 2019;16(2):113–130.
147 Soliman EZ, Lopez F, O'Neal WT, et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the atherosclerosis risk in Communities (ARIC) study. *Circulation*. 2015;131(21):1843–1850.
148 Lee HY, Yang PS, Kim TH, et al. Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. *Sci Rep*. 2017;7(1):12716.
149 Vyas A, Chan PS, Cram P, Nallamothu BK, McNally B, Girotra S. Early coronary angiography and survival after out-of-hospital cardiac arrest. *Circ Cardiovasc Interv*. 2015;8(10):e002321.
150 Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European society of cardiology working group on thrombosis, European association of percutaneous cardiovascular interventions (EAPCI), and European association of acute cardiac care (ACCA) endorsed by the heart rhythm society (HRS), asia-pacific heart rhythm society (APHRS), Latin America heart rhythm society (LAHRS), and cardiac arrhythmia society of southern Africa (CASSA). *Europace*. 2018;21(2):192–193.
151 Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;40(2):87–165.
152 Yasuda J, Nishioka W, Sakudo A, et al. Suppressor mechanism of serum thymic factor on tumor necrosis factor-alpha-induced apoptosis in the mouse pancreatic beta-cell line. *Biochem Biophys Res Commun*. 2003;311(2):501–505.
153 van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. *Eur J Heart Fail*. 2014;16(1):103–111.
154 Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. *Am J Cardiol*. 2003;91(6a):2d–8d.
155 Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008;358(25):2667–2677.
156 Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J Heart Fail*. 2009;11(7):676–683.
157 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383(9921):955–962.
158 Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. *Eur J Heart Fail*. 2015;17(11):1192–1200.
159 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37(27):2129–2200.
160 Hess PL, Sheng S, Matsouaka R, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the get with the guidelines - heart failure program). *Am J Cardiol*. 2020;125(6):894–900.
161 Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. *Eur J Heart Fail*. 2019;21(4):471–479.
162 Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet*. 2014;384(9961):2235–2243.
163 Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med*. 2020;383(14):1305–1316.
164 Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2021;373:n991.
165 Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321(13):1261–1274.
166 Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. *Eur Heart J*. 2019;40(16):1257–1264.
167 Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med*. 2009;360(7):668–678.
168 Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. *Eur Heart J*. 2021;43(12):1219–1230.
169 Rillig A, Borof K, Breithardt G, et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden. *Circulation*. 2022;146(11):836–847.
170 Kim D, Yang PS, You SC, et al. Early rhythm control therapy for atrial fibrillation in low-risk patients : a nationwide propensity score-weighted study. *Ann Intern Med*. 2022;175(10):1356–1365.
171 Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation*. 2016;133(17):1637–1644.
172 Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. *Heart Rhythm*. 2020;17(7):1057–1065.
173 Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. *Circ Arrhythm Electrophysiol*. 2019;12(12):e007731.
174 Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *N Engl J Med*. 2008;359(17):1778–1785.
175 MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. *Heart*. 2011;97(9):740–747.
176 Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. *J Am Coll Cardiol*. 2013;61(18):1894–1903.
177 Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circ Arrhythm Electrophysiol*. 2014;7(1):31–38.
178 Al Halabi S, Qintar M, Hussein A, et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. *JACC Clin Electrophysiol*. 2015;1(3):200–209.

179 Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. *J Am Coll Cardiol*. 2017;70(16):1949–1961.
180 Elgendy AY, Mahmoud AN, Khan MS, et al. Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction. *Am J Cardiol*. 2018;122(5):806–813.
181 Khan SU, Rahman H, Talluri S, Kaluski E. The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis. *JACC Clin Electrophysiol*. 2018;4(5):626–635.
182 Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. *N Engl J Med*. 2023;389(15):1380–1389.
183 Peters S. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at the end of the disease story? *Circ J*. 2015;79(2):446.
184 Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Europace*. 2011;13(8):1077–1109.
185 Yeung C, Enriquez A, Suarez-Fuster L, Baranchuk A. Atrial fibrillation in patients with inherited cardiomyopathies. *Europace*. 2019;21(1):22–32.
186 Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2002;39(2):301–307.
187 Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation*. 2001;104(21):2517–2524.
188 Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. *Heart*. 2017;103(19):1496–1501.
189 Fauchier L, Bisson A, Bodin A, et al. Ischemic stroke in patients with hypertrophic cardiomyopathy according to presence or absence of atrial fibrillation. *Stroke*. 2022;53(2):497–504.
190 Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, Lip GYH. Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data. *J Am Heart Assoc*. 2021;10(23):e021970.
191 Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC). *Eur Heart J*. 2014;35(39):2733–2779.
192 Rodriguez-Manero M, Lopez-Pardo E, Cordero A, et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. *Int J Chron Obstruct Pulmon Dis*. 2019;14:371–380.
193 Simons SO, Elliott A, Sastry M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. *Eur Heart J*. 2021;42(5):532–540.
194 Noubiap JJ, Tu SJ, Emami M, Middeldorp ME, Elliott AD, Sanders P. Incident atrial fibrillation in relation to ventilatory parameters: a prospective cohort study. *Can J Cardiol*. 2023;39(5):614–622.
195 Pisters R, Nieuwlaat R, Prins MH, et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. *Europace*. 2012;14(5):666–674.
196 Roh SY, Choi JI, Lee JY, et al. Catheter ablation of atrial fibrillation in patients with chronic lung disease. *Circ Arrhythm Electrophysiol*. 2011;4(6):815–822.
197 Gu J, Liu X, Tan H, et al. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. *J Cardiovasc Electrophysiol*. 2013;24(2):148–154.
198 Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. *Lancet Respir Med*. 2016;4(2):149–164.
199 Dransfield MT, McAllister DA, Anderson JA, et al. Beta-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An observational substudy of SUMMIT. *Ann Am Thorac Soc*. 2018;15(5):608–614.
200 You SC, An MH, Yoon D, et al. Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease. *Heart Rhythm*. 2018;15(12):1825–1832.
201 Cohen AJ, Brauer M, Burnett R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. *Lancet*. 2017;389(10082):1907–1918.
202 Makri A, Stilianakis NI. Vulnerability to air pollution health effects. *Int J Hyg Environ Health*. 2008;211(3-4):326–336.
203 de Bont J, Jaganathan S, Dahlquist M, Persson A, Stafoggia M, Ljungman P. Ambient air pollution and cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. *J Intern Med*. 2022;291(6):779–800.
204 Pranata R, Vania R, Tondas AE, Setianto B, Santoso A. A time-to-event analysis on air pollutants with the risk of cardiovascular disease and mortality: a systematic review and meta-analysis of 84 cohort studies. *J Evid Based Med*. 2020;13(2):102–115.
205 Shao Q, Liu T, Korantzopoulos P, Zhang Z, Zhao J, Li G. Association between air pollution and development of atrial fibrillation: a meta-analysis of observational studies. *Heart Lung*. 2016;45(6):557–562.
206 Yue C, Yang F, Wang L, Li F, Chen Y. Association between fine particulate matter and atrial fibrillation in implantable cardioverter defibrillator patients: a systematic review and meta-analysis. *J Interv Card Electrophysiol*. 2020;59(3):595–601.
207 Yue C, Yang F, Li F, Chen Y. Association between air pollutants and atrial fibrillation in general population: a systematic review and meta-analysis. *Ecotoxicol Environ Saf*. 2021;208:111508.
208 Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. *Nat Rev Nephrol*. 2018;14(5):337–351.
209 Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. *Europace*. 2015;17(8):1169–1196.
210 Yu HT, Yang PS, Kim TH, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. *Stroke*. 2018;49(10):2421–2429.
211 Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. *Circulation*. 2016;134(1):24–36.
212 Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. *JAMA Cardiol*. 2016;1(4):451–460.
213 Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *Eur Heart J*. 2011;32(19):2387–2394.
214 Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. *Circulation*. 2018;138(15):1519–1529.
215 Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. *Am J Med*. 2019;132(9):1078–1083.
216 Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. *Heart Rhythm*. 2011;8(3):335–341.
217 Garg PK, O'Neal WT, Diez-Roux AV, Alonso A, Soliman EZ, Heckbert S. Negative affect and risk of atrial fibrillation: mesa. *J Am Heart Assoc*. 2019;8(1):e010603.
218 Bae NY, Lee SR, Choi EK, et al. Impact of mental disorders on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study. *Cardiovasc Diabetol*. 2022;21(1):251.
219 Wu H, Li C, Li B, Zheng T, Feng K, Wu Y. Psychological factors and risk of atrial fibrillation: a meta-analysis and systematic review. *Int J Cardiol*. 2022;362:85–92.
220 Feng T, Malmo V, Laugsand LE, et al. Symptoms of anxiety and depression and risk of atrial fibrillation-The HUNT study. *Int J Cardiol*. 2020;306:95–100.

221 Chou RH, Lo LW, Liou YJ, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: a nationwide nested case-control study. *Int J Cardiol*. 2017;227:134–140.
222 Hojen AA, Nielsen PB, Riahi S, et al. Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: a nationwide cohort study. *Br J Clin Pharmacol*. 2022;88(8):3847–3855.
223 Fenger-Gron M, Vestergaard CH, Ribe AR, et al. Association between bipolar disorder or schizophrenia and oral anticoagulation use in Danish adults with incident or prevalent atrial fibrillation. *JAMA Netw Open*. 2021;4(5):e2110096.
224 Farran D, Feely O, Ashworth M, Gaughran F. Anticoagulation therapy and outcomes in patients with atrial fibrillation and serious mental illness: a systematic review and meta-analysis. *J Psychiatr Res*. 2022;156:737–753.
225 Teppo K, Jaakkola J, Airaksinen KEJ, et al. Mental health conditions and nonpersistence of direct oral anticoagulant use in patients with incident atrial fibrillation: a nationwide cohort study. *J Am Heart Assoc*. 2022;11(6):e024119.
226 Sogaard M, Skjoth F, Kjaeldgaard JN, Larsen TB, Hjortshoj SP, Riahi S. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. *BMJ Open*. 2017;7(12):e018209.
227 Kubo T, Sato T, Noguchi T, et al. Influences of donepezil on cardiovascular system–possible therapeutic benefits for heart failure–donepezil cardiac test registry (DOCTER) study. *J Cardiovasc Pharmacol*. 2012;60(3):310–314.
228 Papanastasiou CA, Theochari CA, Zareifopoulos N, et al. Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer's disease: a systematic review and meta-analysis. *J Gen Intern Med*. 2021;36(10):3122–3135.
229 Kim D, Yang PS, Yu HT, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. *Eur Heart J*. 2019;40(28):2313–2323.
230 Kim D, Yang PS, Lip GYH, Joung B. Atrial fibrillation increases the risk of early-onset dementia in the general population: data from a population-based cohort. *J Clin Med*. 2020;9(11):3665.
231 Nagata K, Inoue H, Yamashita T, et al. Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE Registry. *BMJ Neurol Open*. 2023;5(1):e000370.
232 Chen LY, Norby FL, Gottesman RF, et al. Association of atrial fibrillation with cognitive decline and dementia over 20 Years: the ARIC-NCS (atherosclerosis risk in Communities neurocognitive study). *J Am Heart Assoc*. 2018;7(6):e007301.
233 Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. *Heart Rhythm*. 2010;7(4):433–437.
234 Kogelschatz B, Zenger B, Steinberg BA, Ranjan R, Jared Bunch T. Atrial fibrillation and the risk of early-onset dementia an cognitive decline: an updated review. *Trends Cardiovasc Med*. 2023.
235 Gardarsdottir M, Sigurdsson S, Aspelund T, et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. *Europace*. 2018;20(8):1252–1258.
236 Kerr AJ, Simmonds MB, Stewart RA. Influence of heart rate on stroke volume variability in atrial fibrillation in patients with normal and impaired left ventricular function. *Am J Cardiol*. 1998;82(12):1496–1500.
237 Conen D, Rodondi N, Muller A, et al. Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation. *J Am Coll Cardiol*. 2019;73(9):989–999.
238 Kim D, Yang PS, Sung JH, et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. *Eur Heart J*. 2020;41(47):4483–4493.
239 Bodagh N, Yap R, Kotadia I, et al. Impact of catheter ablation versus medical therapy on cognitive function in atrial fibrillation: a systematic review. *J Interv Card Electrophysiol*. 2022;65(1):271–286.
240 Saglietto A, Ballatore A, Xhakupi H, De Ferrari GM, Anselmino M. Association of catheter ablation and reduced incidence of dementia among patients with atrial fibrillation during long-term follow-up: a systematic review and meta-analysis of observational studies. *J Cardiovasc Dev Dis*. 2022;9(5):140.
241 Salvadori E, Barucci E, Barbato C, et al. Cognitive phenotypes and factors associated with cognitive decline in a cohort of older patients with atrial fibrillation: the Strat-AF study. *Eur J Neurol*. 2023;30(4):849–860.
242 Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. *Eur Heart J*. 2018;39(6):453–460.
243 Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: a population-based study. *Neurology*. 2018;91(19):e1732–e1740.
244 Lin M, Han W, Zhong J, Wu L. A systematic review and meta-analysis to determine the effect of oral anticoagulants on incidence of dementia in patients with atrial fibrillation. *Int J Clin Pract*. 2021;75(10):e14269.
245 Lee SR, Choi EK, Park SH, et al. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. *Stroke*. 2021;52(11):3459–3468.
246 Kim D, Yang PS, Jang E, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. *Europace*. 2021;23(2):184–195.
247 Kim D, Yang PS, You SC, et al. Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study. *Age Ageing*. 2022;51(1):afab248.
248 Wu CY, Iskander C, Wang C, et al. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. *Diabetes Care*. 2023;46(2):297–304.
249 Park SH, Lee SR, Choi EK, et al. Low risk of dementia in patients with newly diagnosed atrial fibrillation and a clustering of healthy lifestyle behaviors: a nationwide population-based cohort study. *J Am Heart Assoc*. 2022;11(7):e023739.
250 Yang PS, Sung JH, Jang E, et al. The effect of integrated care management on dementia in atrial fibrillation. *J Clin Med*. 2020;9(6):1696.
251 He L, He R, Huang J, Zou C, Fan Y. Impact of frailty on all-cause mortality and major bleeding in patients with atrial fibrillation: a meta-analysis. *Ageing Res Rev*. 2022;73:101527.
252 Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. *J Am Geriatr Soc*. 2012;60(8):1487–1492.
253 Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. *Age Ageing*. 2019;48(2):196–203.
254 Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. *Ageing Res Rev*. 2022;79:101652.
255 Wilkinson C, Clegg A, Todd O, et al. Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study. *Age Ageing*. 2021;50(3):772–779.
256 Frewen J, Finucane C, Cronin H, et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. *QJM*. 2013;106(5):415–424.
257 Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. *BMC Med*. 2020;18(1):401.
258 Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. *J Intern Med*. 2021;289(1):42–52.
259 Kim D, Yang PS, Sung JH, et al. Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. *Stroke*. 2022;53(6):1873–1882.
260 Yu GI, Kim D, Sung JH, et al. Impact of frailty on early rhythm control outcomes in older adults with atrial fibrillation: a nationwide cohort study. *Front Cardiovasc Med*. 2022;9:1050744.
261 Yang PS, Sung JH, Jang E, et al. Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: a nationwide cohort study. *J Arrhythm*. 2020;36(4):668–677.
262 Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. *Mayo Clin Proc*. 2019;94(12):2427–2436.
263 Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. *Thromb Haemost*. 2022;122(1):142–150.
264 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012;380(9836):37–43.

265 Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. *Clin Res Cardiol*. 2016;105(5):412–420.
266 Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. *Circulation*. 2016;133(4):352–360.
267 Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. *BMJ*. 2016;353:i2868.
268 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. *Thromb Haemost*. 2010;104(6):1099–1105.
269 Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(5):405–414.
270 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Thromb Haemost*. 2023. https://doi.org/10.1055/s-0043-1769735.
271 Nicolau AM, Corbalan R, Nicolau JC, et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. *Eur Heart J Cardiovasc Pharmacother*. 2020;6(3):167–175.
272 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. *Thromb Haemost*. 2023. https://doi.org/10.1055/s-0043-1770724.
273 Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH, Chi ORI. Effects of the atrial fibrillation better care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF registry. *J Am Heart Assoc*. 2022;11(7):e024319.
274 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. *J Am Heart Assoc*. 2020;9(10):e014932.
275 Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. *Circulation*. 2014;129(8):837–847.
276 Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. *Circulation*. 2018;137(12):e67–e492.
277 Scheuermeyer FX, Mackay M, Christenson J, et al. There are sex differences in the demographics and risk profiles of emergency department (ED) patients with atrial fibrillation and flutter, but no apparent differences in ED management or outcomes. *Acad Emerg Med*. 2015;22(9):1067–1075.
278 Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation*. 1998;98(10):946–952.
279 Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA(2)DS(2)-VA score rather than CHA(2)DS(2)-VASc? *Circulation*. 2018;137(8):832–840.
280 Shantsila E, Wolff A, Lip GY, Lane DA. Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. *Int J Clin Pract*. 2015;69(8):840–845.
281 Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. *Am J Cardiol*. 2000;86(7):764–768.
282 Svensson T, Kitlinski M, Engstrom G, Melander O. Psychological stress and risk of incident atrial fibrillation in men and women with known atrial fibrillation genetic risk scores. *Sci Rep*. 2017;7:42613.
283 Westcott SK, Beach LY, Matsushita F, et al. Relationship between psychosocial stressors and atrial fibrillation in women >45 Years of age. *Am J Cardiol*. 2018;122(10):1684–1687.
284 Gleason KT, Dennison Himmelfarb CR, Ford DE, et al. Association of sex, age and education level with patient reported outcomes in atrial fibrillation. *BMC Cardiovasc Disord*. 2019;19(1):85.
285 Aurelius T, Ken-Dror G, Sharma SD, et al. Atrial fibrillation in UK South Asian hospitalized ischemic stroke patients: the BRAINS study. *PLoS One*. 2023;18(2):e0281014.
286 Robson J, Garriga C, Coupland C, Hippisley-Cox J. NHS Health Checks: an observational study of equity and outcomes 2009-2017. *Br J Gen Pract*. 2021;71(710):e701–e710.
287 Mou L, Norby FL, Chen LY, et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (atherosclerosis risk in Communities). *Circ Arrhythm Electrophysiol*. 2018;11(7):e006350.
288 Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. *Ann Epidemiol*. 2015;25(2):71–76.
289 Li H, Song X, Liang Y, et al. Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990-2019: results from a global burden of disease study, 2019. *BMC Public Health*. 2022;22(1):2015.
290 Magnani JW, Norby FL, Agarwal SK, et al. Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the atherosclerosis risk in Communities (ARIC) study. *JAMA Cardiol*. 2016;1(4):433–441.
291 Zhang J, Johnsen SP, Guo Y, Lip GYH. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. *Card Electrophysiol Clin*. 2021;13(1):1–23.
292 Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. *Eur Heart J Qual Care Clin Outcomes*. 2021;7(6):574–582.
293 Du X, Guo L, Xia S, et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. *Heart*. 2021;107(7):535–541.
294 Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. *Eur Heart J*. 2009;30(9):1113–1120.
295 Lunde ED, Nielsen PB, Riahi S, et al. Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. *Expet Rev Cardiovasc Ther*. 2018;16(11):857–873.
296 Wandell P, Carlsson AC, Gasevic D, Sundquist J, Sundquist K. Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: a cohort study of patients treated in primary care in Sweden. *Int J Cardiol*. 2016;202:776–781.
297 Hagengaard L, Andersen MP, Polcwiartek C, et al. Socioeconomic differences in outcomes after hospital admission for atrial fibrillation or flutter. *Eur Heart J Qual Care Clin Outcomes*. 2021;7(3):295–303.
298 Olsen F, Uleberg B, Jacobsen BK, et al. Socioeconomic and geographic differences in ablation of atrial fibrillation in Norway - a national cohort study. *BMC Public Health*. 2022;22(1):303.
299 Teppo K, Jaakkola J, Biancari F, et al. Socioeconomic factors and bleeding events in patients with incident atrial fibrillation: a Finnish nationwide cohort study. *Int J Cardiol Heart Vasc*. 2022;43:101131.
300 McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381(21):1995–2008.